Miruvor
Sign up
The short answer

What studies of Chinese, Japanese and Korean herbal medicine found

81papers on Chinese, Japanese and Korean herbal medicine
887people in 17 studies testing Chinese, Japanese and Korean herbal medicine alone, and 1,224 patients in 1 health-record study, counted apart
5randomised trials, the strongest kind of study

At a glance, by condition

Long COVID: C Might help, very uncertain

Based on the strongest evidence, compared with another group, not randomised and studies with no comparison group (very low certainty): 11 of 13 findings are C.

11 outcomes rated · see each below

ME/CFS: D Little or no difference

Based on the strongest evidence, placebo trials and the placebo trial (low certainty): 2 findings, all D.

8 outcomes rated · see each below

Both together: C Might help, very uncertain

Based on the strongest evidence, studies with no comparison group (very low certainty), for overall symptoms.

1 outcome rated · see each below

How we got this

Each condition’s headline comes from its graded findings (one for each outcome and kind of study) rated with the highest certainty: the grade most of them share; a tie goes to the finding with the most people, then the most studies, then the outcome’s name. It sums up the grades below, and conditions are never combined.

What this means: For long COVID, Chinese, Japanese and Korean herbal medicine might help some people, but research can’t show it yet. For ME/CFS, studies found little or no difference with Chinese, Japanese and Korean herbal medicine. For long COVID and ME/CFS studied together, Chinese, Japanese and Korean herbal medicine might help some people, but research can’t show it yet. If you’re thinking about it, talk it through with a doctor who knows ME/CFS or long COVID.

Ask about this treatment

Sign up free to read the rest of what studies found.

You’ll see the full picture: how each symptom fared, every grade with its reasons, side effects, the doses studied and all 81 papers.

The grades, in plain words

Each outcome gets a direction, a certainty and a letter read from the two. Certainty is judged with GRADE, the method Cochrane and WHO use.

  1. A
    HelpsImprovement, high certainty
    Probably helpsImprovement, moderate certainty
  2. B
    May helpImprovement, low certainty
  3. Chinese, Japanese and Korean herbal medicine · Long COVID is hereChinese, Japanese and Korean herbal medicine · Both together is hereC
    Might help, very uncertainImprovement, very low certainty
    Mixed resultsStudies disagree
  4. Chinese, Japanese and Korean herbal medicine · ME/CFS is hereD
    Little or no differenceStudies found little or no difference
  5. F
    HarmsIt made things worse

By symptom and daily life

Long COVID

Symptoms

Smell and taste loss1 study · 1,224 people took Chinese, Japanese and Korean herbal medicine Improvement C
Very low certainty

Why this grade: Improvement, very low certainty, from controlled studies: serious risk of bias (ROBINS-I); not all results were tested against chance.

Compared with another group, not randomised1,426 in the study · for a total of 14 doses · 200 mL, after breakfast and dinner, twice daily, for a total of 14 doses

Smell and taste loss improved more than in the comparison group.

The evidence is very uncertain about the effect of chinese, Japanese and Korean herbal medicine on smell and taste loss in long COVID. Improvement · very low certainty C

  • Serious risk of bias (ROBINS-I)
  • Not all results were tested against chance
See the 1 study
  1. Traditional Chinese medicine application and evidence analysis of 1426 cases of long COVID: A retrospective study (2024)

    People in the study
    1,426 in the study
    Dose
    200 mL, after breakfast and dinner, twice daily, for a total of 14 doses
    Outcome
    Smell or taste problems
    Effect
    better (not tested)
    Risk of bias
    ROBINS-I: Serious
    Confounding
    Moderate. adjusted for: demographic indices and personal habits (smoking, alcohol consumption, preference for spicy foods) Model adjusted for demographic indices and personal habits (smoking, alcohol consumption, and preference for spicy foods).
    Selection of participants
    Moderate. comparison group: Western medicine control group recruited at the same hospital during the same period We recruited volunteers who met the diagnostic criteria at the same hospital during the same period as the control group for Western medicine treatment
    Classification of interventions
    Moderate. from records after the fact
    Deviations from intended interventions
    NI. not reported for this design
    Missing data
    NI. missing data aren't reported
    Measurement of outcomes
    Serious. self-reported by people who knew their treatment
    Selection of the reported result
    Low. a pre-specified secondary outcome in a registered study
Fatigue3 studies · 196 people took Chinese, Japanese and Korean herbal medicine Improvement C
Very low certainty

Why this grade: Improvement, very low certainty, from studies without a control group: no control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design).

Studies with no comparison group3 studies · 196 people with results

Fatigue improved.

The evidence is very uncertain about the effect of chinese, Japanese and Korean herbal medicine on fatigue in long COVID. Improvement · very low certainty C

  • No control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design)
See the 3 studies
  1. Evaluating myelophil, a 30% ethanol extract of Astragalus membranaceus and Salvia miltiorrhiza, for alleviating fatigue in long COVID: a real-world observational study. (2024)

    People in the study
    50 in the study · 49 started · 49 with outcome data
    Dose
    2,000 mg daily, two MYP capsules orally, twice daily
    Outcome
    physical fatigue Modified Korean version of the Chalder Fatigue Scale (mKCFQ11)
    Effect
    better
    Risk of bias
    before-after study without a control group (JBI checklist for quasi-experimental studies); not rated with RoB 2 or ROBINS-I
  2. Herbal medicine (Kyungok-go) for fatigue in Long COVID patients: A prospective multicenter pilot study. (2026)

    People in the study
    100 in the study
    Dose
    22.5 g twice daily, between meals
    Outcome
    FSS score Fatigue Severity Scale
    Effect
    better
    Risk of bias
    before-after study without a control group (JBI checklist for quasi-experimental studies); not rated with RoB 2 or ROBINS-I
  3. Clinical effects of traditional Chinese herbal medicine management in patients with COVID-19 sequelae: A hospital-based retrospective cohort study in Taiwan. (2024)

    People in the study
    47 in the study
    Dose
    commercial concentrated extract powder
    Outcome
    physical fatigue scores change Chalder Fatigue Questionnaire (CFQ-11)
    Effect
    better
    Risk of bias
    before-after study without a control group (JBI checklist for quasi-experimental studies); not rated with RoB 2 or ROBINS-I
Cognition (brain fog)4 studies · 151 people took Chinese, Japanese and Korean herbal medicine Improvement C
Very low certainty

Why this grade: Improvement, very low certainty, from studies without a control group: no control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design); not all results were tested against chance.

Studies with no comparison group4 studies · 151 people with results

Cognition (brain fog) improved.

The evidence is very uncertain about the effect of chinese, Japanese and Korean herbal medicine on cognition (brain fog) in long COVID. Improvement · very low certainty C

  • No control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design)
  • Not all results were tested against chance
See the 4 studies
  1. Herbal medicine (Kyungok-go) for fatigue in Long COVID patients: A prospective multicenter pilot study. (2026)

    People in the study
    100 in the study
    Dose
    22.5 g twice daily, between meals
    Outcome
    K-MOCA Korean version of the Montreal Cognitive Assessment
    Effect
    better
    Risk of bias
    before-after study without a control group (JBI checklist for quasi-experimental studies); not rated with RoB 2 or ROBINS-I
  2. Evaluating myelophil, a 30% ethanol extract of Astragalus membranaceus and Salvia miltiorrhiza, for alleviating fatigue in long COVID: a real-world observational study. (2024)

    People in the study
    50 in the study · 49 started · 49 with outcome data
    Dose
    2,000 mg daily, two MYP capsules orally, twice daily
    Outcome
    Brain Fog VAS Visual Analog Scale (VAS)
    Effect
    better (not tested)
    Risk of bias
    before-after study without a control group (JBI checklist for quasi-experimental studies); not rated with RoB 2 or ROBINS-I
  3. Integrative strategy for Long COVID neuropsychiatric symptoms: A case report on Kamikihito and Bupleurum-Scutellaria formulas guided by pharmacological rationale. (2026)

    People in the study
    1 in the study
    Dose
    7.5 g/day, Initially
    Outcome
    Brain Fog Score (BFS) Brain Fog Score
    Effect
    better (not tested)
    Risk of bias
    case report or series (JBI checklist for case reports / case series); not rated with RoB 2 or ROBINS-I
  4. Chinese Herbal Treatment For Long COVID Brain Fog, A Case Report (2023)

    People in the study
    1 in the study
    Dose
    5 g of the formula, once in the morning and once at night
    Outcome
    brain fog improved over time
    Effect
    better (not tested)
    Risk of bias
    case report or series (JBI checklist for case reports / case series); not rated with RoB 2 or ROBINS-I
Depression2 studies · 130 people took Chinese, Japanese and Korean herbal medicine Improvement C
Very low certainty

Why this grade: Improvement, very low certainty, from studies without a control group: no control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design).

Studies with no comparison group2 studies · 130 people with results

Depression improved.

The evidence is very uncertain about the effect of chinese, Japanese and Korean herbal medicine on depression in long COVID. Improvement · very low certainty C

  • No control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design)
See the 2 studies
  1. Herbal medicine (Kyungok-go) for fatigue in Long COVID patients: A prospective multicenter pilot study. (2026)

    People in the study
    100 in the study
    Dose
    22.5 g twice daily, between meals
    Outcome
    BDI Beck Depression Inventory
    Effect
    better
    Risk of bias
    before-after study without a control group (JBI checklist for quasi-experimental studies); not rated with RoB 2 or ROBINS-I
  2. Herbal medicines for long COVID: A phase 2 pilot clinical study. (2024)

    People in the study
    45 in the study
    Dose
    one sachet (3.75 g), twice a day before or in between meals
    Outcome
    BDI Beck's Depression Inventory
    Effect
    better
    Risk of bias
    before-after study without a control group (JBI checklist for quasi-experimental studies); not rated with RoB 2 or ROBINS-I
Sleep2 studies · 101 people took Chinese, Japanese and Korean herbal medicine Improvement C
Very low certainty

Why this grade: Improvement, very low certainty, from studies without a control group: no control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design); not all results were tested against chance.

Studies with no comparison group2 studies · 101 people with results

Sleep improved.

The evidence is very uncertain about the effect of chinese, Japanese and Korean herbal medicine on sleep in long COVID. Improvement · very low certainty C

  • No control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design)
  • Not all results were tested against chance
See the 2 studies
  1. Herbal medicine (Kyungok-go) for fatigue in Long COVID patients: A prospective multicenter pilot study. (2026)

    People in the study
    100 in the study
    Dose
    22.5 g twice daily, between meals
    Outcome
    PSQI-K Korean version of the Pittsburgh Sleep Quality Index
    Effect
    better
    Risk of bias
    before-after study without a control group (JBI checklist for quasi-experimental studies); not rated with RoB 2 or ROBINS-I
  2. Integrative strategy for Long COVID neuropsychiatric symptoms: A case report on Kamikihito and Bupleurum-Scutellaria formulas guided by pharmacological rationale. (2026)

    People in the study
    1 in the study
    Dose
    7.5 g/day, Initially
    Outcome
    insomnia
    Effect
    better (not tested)
    Risk of bias
    case report or series (JBI checklist for case reports / case series); not rated with RoB 2 or ROBINS-I
Low mood or anxiety2 studies · 48 people took Chinese, Japanese and Korean herbal medicine Improvement C
Very low certainty

Why this grade: Improvement, very low certainty, from studies without a control group: no control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design); few people (48 in all); not all results were tested against chance.

Studies with no comparison group2 studies · 48 people with results

Low mood or anxiety improved.

The evidence is very uncertain about the effect of chinese, Japanese and Korean herbal medicine on low mood or anxiety in long COVID. Improvement · very low certainty C

  • No control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design)
  • Few people (48 in all)
  • Not all results were tested against chance
See the 2 studies
  1. Integrative strategy for Long COVID neuropsychiatric symptoms: A case report on Kamikihito and Bupleurum-Scutellaria formulas guided by pharmacological rationale. (2026)

    People in the study
    1 in the study
    Dose
    7.5 g/day, Initially
    Outcome
    SF-12 MCS 12-Item Short-Form Health Survey
    Effect
    better (not tested)
    Risk of bias
    case report or series (JBI checklist for case reports / case series); not rated with RoB 2 or ROBINS-I
  2. Clinical effects of traditional Chinese herbal medicine management in patients with COVID-19 sequelae: A hospital-based retrospective cohort study in Taiwan. (2024)

    People in the study
    47 in the study
    Dose
    commercial concentrated extract powder
    Outcome
    proportion of patients in the medium-to-high-grade symptom group assessed using the BSRS-5 Brief Symptom Rating Scale (BSRS-5)
    Effect
    better (not tested)
    Risk of bias
    before-after study without a control group (JBI checklist for quasi-experimental studies); not rated with RoB 2 or ROBINS-I
Breathlessness1 study · 47 people took Chinese, Japanese and Korean herbal medicine Improvement C
Very low certainty

Why this grade: Improvement, very low certainty, from studies without a control group: no control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design); few people (47 in all).

Studies with no comparison group47 in the study · after 14 and 28 days of treatment · commercial concentrated extract powder

Breathlessness improved.

The evidence is very uncertain about the effect of chinese, Japanese and Korean herbal medicine on breathlessness in long COVID. Improvement · very low certainty C

  • No control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design)
  • Few people (47 in all)
See the 1 study
  1. Clinical effects of traditional Chinese herbal medicine management in patients with COVID-19 sequelae: A hospital-based retrospective cohort study in Taiwan. (2024)

    People in the study
    47 in the study
    Dose
    commercial concentrated extract powder
    Outcome
    proportion of patients in the medium-to-high-grade symptom group assessed using CAT Chronic Obstructive Pulmonary Disease (COPD) Assessment Tool (CAT)
    Effect
    better
    Risk of bias
    before-after study without a control group (JBI checklist for quasi-experimental studies); not rated with RoB 2 or ROBINS-I
Pain1 study · 1,224 people took Chinese, Japanese and Korean herbal medicine Little or no difference D
Very low certainty

Why this grade: Little or no difference, very low certainty, from controlled studies: serious risk of bias (ROBINS-I); the change wasn't shown to be more than chance.

Compared with another group, not randomised1,426 in the study · for a total of 14 doses · 200 mL, after breakfast and dinner, twice daily, for a total of 14 doses

No clear difference in pain.

The evidence is very uncertain about the effect of chinese, Japanese and Korean herbal medicine on pain in long COVID. Little or no difference · very low certainty D

  • Serious risk of bias (ROBINS-I)
  • The change wasn't shown to be more than chance
See the 1 study
  1. Traditional Chinese medicine application and evidence analysis of 1426 cases of long COVID: A retrospective study (2024)

    People in the study
    1,426 in the study
    Dose
    200 mL, after breakfast and dinner, twice daily, for a total of 14 doses
    Outcome
    Headache
    Effect
    no clear difference
    Risk of bias
    ROBINS-I: Serious
    Confounding
    Moderate. adjusted for: demographic indices and personal habits (smoking, alcohol consumption, preference for spicy foods) Model adjusted for demographic indices and personal habits (smoking, alcohol consumption, and preference for spicy foods).
    Selection of participants
    Moderate. comparison group: Western medicine control group recruited at the same hospital during the same period We recruited volunteers who met the diagnostic criteria at the same hospital during the same period as the control group for Western medicine treatment
    Classification of interventions
    Moderate. from records after the fact
    Deviations from intended interventions
    NI. not reported for this design
    Missing data
    NI. missing data aren't reported
    Measurement of outcomes
    Serious. self-reported by people who knew their treatment
    Selection of the reported result
    Low. a pre-specified secondary outcome in a registered study

Daily life and health overall

Overall symptoms5 studies · 1,274 people took Chinese, Japanese and Korean herbal medicine Improvement C
Very low certainty

Why this grade: Improvement, very low certainty, from controlled studies: serious risk of bias (ROBINS-I); effect size 0.15 (very small); the benefit is very small.

Compared with another group, not randomised1,426 in the study · for a total of 14 doses · 200 mL, after breakfast and dinner, twice daily, for a total of 14 doses

Overall symptoms improved more than in the comparison group.

The evidence is very uncertain about the effect of chinese, Japanese and Korean herbal medicine on overall symptoms in long COVID. Improvement · very low certainty C

  • Serious risk of bias (ROBINS-I)
  • Effect size 0.15 (very small)
  • The benefit is very small

How big was the difference?

0.15, very small. The effect size compares Chinese, Japanese and Korean herbal medicine with wm group.

Studies with no comparison group4 studies · 50 people with results

Overall symptoms improved.

The evidence is very uncertain about the effect of chinese, Japanese and Korean herbal medicine on overall symptoms in long COVID. Improvement · very low certainty C

  • No control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design)
  • Not all results were tested against chance

Combination: Chinese, Japanese and Korean herbal medicine + Acupuncture + BL132,067 in the study · 1,331 with outcome data

Explainable machine learning model and nomogram for predicting the efficacy of Traditional Chinese Medicine in treating Long COVID: a retrospective study. (2025): effective treatment, better (not tested).

Shown, not counted: Chinese, Japanese and Korean herbal medicine was given together with other treatments.

Combination: Chinese, Japanese and Korean herbal medicine + proton pump inhibitor + Epipharyngeal abrasive therapy (EAT) + Acupuncture + Moxibustion + Zinc + Antihistamines (unspecified) + Mirtazapine (Remeron) + Sleeping pills (unspecified) + Nasal saline rinses and sprays (neti pot)128 in the study · 114 with outcome data

Factors involved in the improvement of prolonged symptoms in patients with COVID-19 treated with Japanese traditional (Kampo) medicine: A single-center, prospective, observational study. (2026): the end of visit milestone, better (not tested).

Shown, not counted: Chinese, Japanese and Korean herbal medicine was given together with other treatments.

See the 5 studies
  1. Traditional Chinese medicine application and evidence analysis of 1426 cases of long COVID: A retrospective study (2024)

    People in the study
    1,426 in the study
    Dose
    200 mL, after breakfast and dinner, twice daily, for a total of 14 doses
    Outcome
    TCM syndrome scores (TCM group vs WM group after treatment)
    Effect
    better
    Risk of bias
    ROBINS-I: Serious
    Confounding
    Moderate. adjusted for: demographic indices and personal habits (smoking, alcohol consumption, preference for spicy foods) Model adjusted for demographic indices and personal habits (smoking, alcohol consumption, and preference for spicy foods).
    Selection of participants
    Moderate. comparison group: Western medicine control group recruited at the same hospital during the same period We recruited volunteers who met the diagnostic criteria at the same hospital during the same period as the control group for Western medicine treatment
    Classification of interventions
    Moderate. from records after the fact
    Deviations from intended interventions
    NI. not reported for this design
    Missing data
    NI. missing data aren't reported
    Measurement of outcomes
    Serious. self-reported by people who knew their treatment
    Selection of the reported result
    Low. a pre-specified primary outcome in a registered study
  2. Integrative strategy for Long COVID neuropsychiatric symptoms: A case report on Kamikihito and Bupleurum-Scutellaria formulas guided by pharmacological rationale. (2026)

    People in the study
    1 in the study
    Dose
    7.5 g/day, Initially
    Outcome
    symptoms
    Effect
    better (not tested)
    Risk of bias
    case report or series (JBI checklist for case reports / case series); not rated with RoB 2 or ROBINS-I
  3. Late-Onset Hypogonadism in a Male Patient with Long COVID Diagnosed by Exclusion of ME/CFS. (2022)

    People in the study
    1 in the study
    Dose
    initiated
    Outcome
    patient’s symptoms
    Effect
    better (not tested)
    Risk of bias
    case report or series (JBI checklist for case reports / case series); not rated with RoB 2 or ROBINS-I
  4. Clinical effects of traditional Chinese herbal medicine management in patients with COVID-19 sequelae: A hospital-based retrospective cohort study in Taiwan. (2024)

    People in the study
    47 in the study
    Dose
    commercial concentrated extract powder
    Outcome
    proportion of patients with three types of co-occurrence symptoms
    Effect
    better (not tested)
    Risk of bias
    before-after study without a control group (JBI checklist for quasi-experimental studies); not rated with RoB 2 or ROBINS-I
  5. Chinese Herbal Treatment For Long COVID Brain Fog, A Case Report (2023)

    People in the study
    1 in the study
    Dose
    5 g of the formula, once in the morning and once at night
    Outcome
    feeling better
    Effect
    better (not tested)
    Risk of bias
    case report or series (JBI checklist for case reports / case series); not rated with RoB 2 or ROBINS-I
Daily functioning3 studies · 102 people took Chinese, Japanese and Korean herbal medicine Improvement C
Very low certainty

Why this grade: Improvement, very low certainty, from studies without a control group: no control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design); not all results were tested against chance; the studies disagree.

Studies with no comparison group3 studies · 102 people with results

Daily functioning improved.

The evidence is very uncertain about the effect of chinese, Japanese and Korean herbal medicine on daily functioning in long COVID. Improvement · very low certainty C

  • No control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design)
  • Not all results were tested against chance
  • The studies disagree

Combination: Chinese, Japanese and Korean herbal medicine + proton pump inhibitor + Epipharyngeal abrasive therapy (EAT) + Acupuncture + Moxibustion + Zinc + Antihistamines (unspecified) + Mirtazapine (Remeron) + Sleeping pills (unspecified) + Nasal saline rinses and sprays (neti pot)128 in the study · 114 with outcome data

Factors involved in the improvement of prolonged symptoms in patients with COVID-19 treated with Japanese traditional (Kampo) medicine: A single-center, prospective, observational study. (2026): PS ≤ 2, better (not tested).

Shown, not counted: Chinese, Japanese and Korean herbal medicine was given together with other treatments.

See the 3 studies
  1. Herbal medicine (Kyungok-go) for fatigue in Long COVID patients: A prospective multicenter pilot study. (2026)

    People in the study
    100 in the study
    Dose
    22.5 g twice daily, between meals
    Outcome
    Standing balance Short Physical Performance Battery
    Effect
    no clear difference
    Risk of bias
    before-after study without a control group (JBI checklist for quasi-experimental studies); not rated with RoB 2 or ROBINS-I
  2. Integrative strategy for Long COVID neuropsychiatric symptoms: A case report on Kamikihito and Bupleurum-Scutellaria formulas guided by pharmacological rationale. (2026)

    People in the study
    1 in the study
    Dose
    7.5 g/day, Initially
    Outcome
    SF-12 RCS 12-Item Short-Form Health Survey
    Effect
    better (not tested)
    Risk of bias
    case report or series (JBI checklist for case reports / case series); not rated with RoB 2 or ROBINS-I
  3. Chinese Herbal Treatment For Long COVID Brain Fog, A Case Report (2023)

    People in the study
    1 in the study
    Dose
    5 g of the formula, once in the morning and once at night
    Outcome
    regular daily tasks
    Effect
    better (not tested)
    Risk of bias
    case report or series (JBI checklist for case reports / case series); not rated with RoB 2 or ROBINS-I
Quality of life4 studies · 180 people took Chinese, Japanese and Korean herbal medicine Little or no difference D
Very low certainty

Why this grade: Little or no difference, very low certainty, from controlled studies: serious risk of bias (ROBINS-I); few people (45 in all).

Compared with another group, not randomised45 in the study · 12 weeks · one sachet (3.75 g), twice a day before or in between meals

No clear difference in quality of life.

The evidence is very uncertain about the effect of chinese, Japanese and Korean herbal medicine on quality of life in long COVID. Little or no difference · very low certainty D

  • Serious risk of bias (ROBINS-I)
  • Few people (45 in all)

Studies with no comparison group3 studies · 150 people with results

Quality of life improved.

The evidence is very uncertain about the effect of chinese, Japanese and Korean herbal medicine on quality of life in long COVID. Improvement · very low certainty C

  • No control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design)
  • Not all results were tested against chance
  • The studies disagree

Combination: Ethyl loflazepate + Agomelatine (Valdoxan) + Mosapride + Pancreatic enzymes (Creon, Zenpep) + Simethicone (Gas-X) + Tegoprazan + Chinese, Japanese and Korean herbal medicine + Acupuncture + Moxibustion1 in the study

Integrative personalized medicine care for adjustment disorder of a post-COVID-19 patient: A CARE-compliant case report. (2024): EQ-5D-5L scores, better (not tested).

Shown, not counted: Chinese, Japanese and Korean herbal medicine was given together with other treatments.

See the 4 studies
  1. Herbal medicines for long COVID: A phase 2 pilot clinical study. (2024)

    People in the study
    45 in the study
    Dose
    one sachet (3.75 g), twice a day before or in between meals
    Outcome
    EQ-5D-5L Standardized 5-level EuroQol 5-Dimensional Questionnaire
    Effect
    no clear difference
    Risk of bias
    ROBINS-I: Serious
    Confounding
    NI. adjustment for confounding isn't reported
    Selection of participants
    Moderate. comparison group: assigned by symptom type and KM syndrome differentiation assigned to the appropriate herbal medicine intervention group according to their specific sub-syndrome differentiation pattern
    Classification of interventions
    Low. assigned and recorded at the start
    Deviations from intended interventions
    NI. not reported for this design
    Missing data
    Moderate. missing data: intention-to-treat with last observation carried forward Statistical analysis was conducted on an intention-to-treat basis, and the last observation carried forward analysis was employed to handle missing data
    Measurement of outcomes
    Serious. self-reported by people who knew their treatment
    Selection of the reported result
    Low. a pre-specified secondary outcome in a registered study
  2. Herbal medicine (Kyungok-go) for fatigue in Long COVID patients: A prospective multicenter pilot study. (2026)

    People in the study
    100 in the study
    Dose
    22.5 g twice daily, between meals
    Outcome
    EQ-5D-5L EuroQol 5-Dimension, 5-Level
    Effect
    no clear difference
    Risk of bias
    before-after study without a control group (JBI checklist for quasi-experimental studies); not rated with RoB 2 or ROBINS-I
  3. Evaluating myelophil, a 30% ethanol extract of Astragalus membranaceus and Salvia miltiorrhiza, for alleviating fatigue in long COVID: a real-world observational study. (2024)

    People in the study
    50 in the study · 49 started · 49 with outcome data
    Dose
    2,000 mg daily, two MYP capsules orally, twice daily
    Outcome
    SF-12 short form 12 (SF-12)
    Effect
    better (not tested)
    Risk of bias
    before-after study without a control group (JBI checklist for quasi-experimental studies); not rated with RoB 2 or ROBINS-I
  4. Integrative strategy for Long COVID neuropsychiatric symptoms: A case report on Kamikihito and Bupleurum-Scutellaria formulas guided by pharmacological rationale. (2026)

    People in the study
    1 in the study
    Dose
    7.5 g/day, Initially
    Outcome
    EQ-5D-5L HR-QOL The EuroQol 5 dimensions 5 levels
    Effect
    better (not tested)
    Risk of bias
    case report or series (JBI checklist for case reports / case series); not rated with RoB 2 or ROBINS-I

ME/CFS

Symptoms

Fatigue5 studies · 359 people took Chinese, Japanese and Korean herbal medicine Improvement C
Very low certainty

Why this grade: Improvement, very low certainty, from randomised trials: high risk of bias (RoB 2) in the results that carry most of the weight; the studies disagree; effect size 0.48 (small).

Randomised trials4 studies · 530 people with results

Fatigue improved more than in the comparison group.

The evidence is very uncertain about the effect of chinese, Japanese and Korean herbal medicine on fatigue in ME/CFS. Improvement · very low certainty C

  • High risk of bias (RoB 2) in the results that carry most of the weight
  • The studies disagree
  • Effect size 0.48 (small)

How big was the difference?

0.48, small. The effect size compares Chinese, Japanese and Korean herbal medicine with placebo.

Studies with no comparison group32 in the study

Fatigue improved.

The evidence is very uncertain about the effect of chinese, Japanese and Korean herbal medicine on fatigue in ME/CFS. Improvement · very low certainty C

  • No control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design)
  • Few people (32 in all)
  • Not all results were tested against chance
See the 5 studies
  1. Effectiveness a herbal medicine (Sipjeondaebo-tang) on adults with chronic fatigue syndrome: A randomized, double-blind, placebo-controlled trial. (2021)

    People in the study
    96 randomised
    Dose
    9 g daily (3 g each time, 3 times a day, before or between meals)
    Outcome
    FSS Fatigue Severity Scale
    Effect
    better
    Risk of bias
    RoB 2: Some concerns
    Randomisation process
    Some concerns
    Deviations from intended interventions
    Some concerns
    Missing outcome data
    Low
    Measurement of the outcome
    Low
    Selection of the reported result
    Low
  2. Sijunzi decoction, a classical Chinese herbal formula, improves fatigue symptoms with changes in gut microbiota in chronic fatigue syndrome: A randomized, double-blind, placebo-controlled, multi-center clinical trial. (2024)

    People in the study
    127 randomised · 105 analysed
    Dose
    daily dose of 9 g, 9 g, 9 g, and 6 g, granules twice daily, once in the morning and once in the evening after meals
    Outcome
    CGI-CFS, n (%) clinical global impression
    Effect
    no clear difference
    Risk of bias
    RoB 2: Low
    Randomisation process
    Low
    Deviations from intended interventions
    Low
    Missing outcome data
    Low
    Measurement of the outcome
    Low
    Selection of the reported result
    Low
  3. Effects of Qiye Shen'an Pian Combined with Glutamate and Vitamin B1 on Fatigue State, Immune Function and Quality of Life in Patients with Chronic Fatigue Syndrome. (2024)

    People in the study
    106 randomised
    Dose
    —
    Outcome
    FS-14 scores
    Effect
    better
    Risk of bias
    RoB 2: High
    Randomisation process
    Some concerns
    Deviations from intended interventions
    High
    Missing outcome data
    High
    Measurement of the outcome
    High
    Selection of the reported result
    Some concerns
  4. Selective serotonin reuptake inhibitor combined with dengzhanshengmai capsule improves the fatigue symptoms: a 12-week open-label pilot study. (2015)

    People in the study
    268 randomised · 223 analysed
    Dose
    1.08 g/day, for 12 weeks
    Outcome
    general fatigue Multidimensional Fatigue Inventory (MFI)-20
    Effect
    better
    Risk of bias
    RoB 2: High
    Randomisation process
    Some concerns
    Deviations from intended interventions
    Some concerns
    Missing outcome data
    High
    Measurement of the outcome
    High
    Selection of the reported result
    Some concerns
  5. Experience of Chronic Fatigue Syndrome Treated with Modified Qinshuyiqi Decoction of Dong Yuan (1997)

    People in the study
    32 in the study
    Dose
    —
    Outcome
    fatigue
    Effect
    better (not tested)
    Risk of bias
    before-after study without a control group (JBI checklist for quasi-experimental studies); not rated with RoB 2 or ROBINS-I
Pain1 study · 32 people took Chinese, Japanese and Korean herbal medicine Improvement C
Very low certainty

Why this grade: Improvement, very low certainty, from studies without a control group: no control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design); few people (32 in all); not all results were tested against chance.

Studies with no comparison group32 in the study

Pain improved.

The evidence is very uncertain about the effect of chinese, Japanese and Korean herbal medicine on pain in ME/CFS. Improvement · very low certainty C

  • No control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design)
  • Few people (32 in all)
  • Not all results were tested against chance
See the 1 study
  1. Experience of Chronic Fatigue Syndrome Treated with Modified Qinshuyiqi Decoction of Dong Yuan (1997)

    People in the study
    32 in the study
    Dose
    —
    Outcome
    ache
    Effect
    better (not tested)
    Risk of bias
    before-after study without a control group (JBI checklist for quasi-experimental studies); not rated with RoB 2 or ROBINS-I
Breathlessness1 study · 1 (few people) person took Chinese, Japanese and Korean herbal medicine Improvement C
Very low certainty

Why this grade: Improvement, very low certainty, from studies without a control group: no control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design); few people (1 in all); not all results were tested against chance.

Studies with no comparison group1 in the study · 2010 to 2026 · after only two weeks (few people)

Breathlessness improved.

The evidence is very uncertain about the effect of chinese, Japanese and Korean herbal medicine on breathlessness in ME/CFS. Improvement · very low certainty C

  • No control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design)
  • Few people (1 in all)
  • Not all results were tested against chance
See the 1 study
  1. Home Alone 2020: A First-Person Case Study on Surviving Modern Pandemics and their Aftermath of Illnesses (2026)

    People in the study
    1 in the study
    Dose
    after only two weeks
    Outcome
    not blue-purple or breathless
    Effect
    better (not tested)
    Risk of bias
    case report or series (JBI checklist for case reports / case series); not rated with RoB 2 or ROBINS-I
Low mood or anxiety2 studies · 158 people took Chinese, Japanese and Korean herbal medicine Little or no difference D
Very low certainty

Why this grade: Little or no difference, very low certainty, from randomised trials: high risk of bias (RoB 2) in the results that carry most of the weight; 319 people in all; a small benefit can't be ruled out; effect size 0.10 (very small).

Randomised trials2 studies · 319 people with results

No clear difference in low mood or anxiety.

The evidence is very uncertain about the effect of chinese, Japanese and Korean herbal medicine on low mood or anxiety in ME/CFS. Little or no difference · very low certainty D

  • High risk of bias (RoB 2) in the results that carry most of the weight
  • 319 people in all; a small benefit can't be ruled out
  • Effect size 0.10 (very small)

How big was the difference?

0.1, very small. The effect size compares Chinese, Japanese and Korean herbal medicine with placebo.

See the 2 studies
  1. Effectiveness a herbal medicine (Sipjeondaebo-tang) on adults with chronic fatigue syndrome: A randomized, double-blind, placebo-controlled trial. (2021)

    People in the study
    96 randomised
    Dose
    9 g daily (3 g each time, 3 times a day, before or between meals)
    Outcome
    VAS score for happiness 100-mm VAS
    Effect
    no clear difference
    Risk of bias
    RoB 2: Some concerns
    Randomisation process
    Some concerns
    Deviations from intended interventions
    Some concerns
    Missing outcome data
    Low
    Measurement of the outcome
    Low
    Selection of the reported result
    Some concerns
  2. Selective serotonin reuptake inhibitor combined with dengzhanshengmai capsule improves the fatigue symptoms: a 12-week open-label pilot study. (2015)

    People in the study
    268 randomised · 223 analysed
    Dose
    1.08 g/day, for 12 weeks
    Outcome
    HAD scores Hospital Anxiety and Depression Scale
    Effect
    no clear difference
    Risk of bias
    RoB 2: High
    Randomisation process
    Some concerns
    Deviations from intended interventions
    Some concerns
    Missing outcome data
    High
    Measurement of the outcome
    High
    Selection of the reported result
    Some concerns
Sleep2 studies · 80 people took Chinese, Japanese and Korean herbal medicine Little or no difference D
Very low certainty

Why this grade: Little or no difference, very low certainty, from randomised trials: some concerns about bias (RoB 2); one trial of 96 people found no clear difference; a small benefit can't be ruled out; effect size 0.15 (very small).

The placebo trial96 randomised · 8 weeks · 9 g daily (3 g each time, 3 times a day, before or between meals)

No clear difference in sleep.

The evidence is very uncertain about the effect of chinese, Japanese and Korean herbal medicine on sleep in ME/CFS. Little or no difference · very low certainty D

  • Some concerns about bias (RoB 2)
  • One trial of 96 people found no clear difference; a small benefit can't be ruled out
  • Effect size 0.15 (very small)

How big was the difference?

0.15, very small. The effect size compares Chinese, Japanese and Korean herbal medicine with placebo.

Studies with no comparison group32 in the study

Sleep improved.

The evidence is very uncertain about the effect of chinese, Japanese and Korean herbal medicine on sleep in ME/CFS. Improvement · very low certainty C

  • No control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design)
  • Few people (32 in all)
  • Not all results were tested against chance
See the 2 studies
  1. Effectiveness a herbal medicine (Sipjeondaebo-tang) on adults with chronic fatigue syndrome: A randomized, double-blind, placebo-controlled trial. (2021)

    People in the study
    96 randomised
    Dose
    9 g daily (3 g each time, 3 times a day, before or between meals)
    Outcome
    PSQI-K Korean version of the Pittsburgh Sleep Quality Index
    Effect
    no clear difference
    Risk of bias
    RoB 2: Some concerns
    Randomisation process
    Some concerns
    Deviations from intended interventions
    Some concerns
    Missing outcome data
    Low
    Measurement of the outcome
    Low
    Selection of the reported result
    Some concerns
  2. Experience of Chronic Fatigue Syndrome Treated with Modified Qinshuyiqi Decoction of Dong Yuan (1997)

    People in the study
    32 in the study
    Dose
    —
    Outcome
    narcolepsy
    Effect
    better (not tested)
    Risk of bias
    before-after study without a control group (JBI checklist for quasi-experimental studies); not rated with RoB 2 or ROBINS-I

Daily life and health overall

Overall symptoms5 studies · 222 people took Chinese, Japanese and Korean herbal medicine Mixed results C
Very low certainty

Why this grade: Mixed results, very low certainty, from randomised trials: high risk of bias (RoB 2) in the results that carry most of the weight; few people (230 in all); the studies disagree; randomised trials found mixed results.

Randomised trials2 studies · 230 people with results

Studies disagree about overall symptoms.

Studies disagree about whether chinese, Japanese and Korean herbal medicine helps overall symptoms. Mixed results · very low certainty C

  • High risk of bias (RoB 2) in the results that carry most of the weight
  • Few people (230 in all)
  • The studies disagree

Studies with no comparison group3 studies · 34 people with results

Overall symptoms improved.

The evidence is very uncertain about the effect of chinese, Japanese and Korean herbal medicine on overall symptoms in ME/CFS. Improvement · very low certainty C

  • No control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design)
  • Few people (34 in all)
  • Not all results were tested against chance
  • The studies disagree

Combination: Massage + Chinese, Japanese and Korean herbal medicine196 randomised

Clinical Observation of Acupoint Massage with Ningshen Decoction in Treatment of Chronic Fatigue Syndrome (2013): total effective rate, better.

Shown, not counted: Chinese, Japanese and Korean herbal medicine was given together with other treatments.

See the 5 studies
  1. Sijunzi decoction, a classical Chinese herbal formula, improves fatigue symptoms with changes in gut microbiota in chronic fatigue syndrome: A randomized, double-blind, placebo-controlled, multi-center clinical trial. (2024)

    People in the study
    127 randomised · 105 analysed
    Dose
    daily dose of 9 g, 9 g, 9 g, and 6 g, granules twice daily, once in the morning and once in the evening after meals
    Outcome
    CGI-health, n (%) clinical global impression
    Effect
    no clear difference
    Risk of bias
    RoB 2: Low
    Randomisation process
    Low
    Deviations from intended interventions
    Low
    Missing outcome data
    Low
    Measurement of the outcome
    Low
    Selection of the reported result
    Low
  2. Clinical Observation of the Treatment of 63 Cases of Chronic Fatigue Syndrome by Using Shengmai Decoction in Combination with Suefu Zhuyu Decoction (2006)

    People in the study
    125 randomised
    Dose
    —
    Outcome
    total effective rate
    Effect
    better
    Risk of bias
    RoB 2: High
    Randomisation process
    Some concerns
    Deviations from intended interventions
    High
    Missing outcome data
    High
    Measurement of the outcome
    High
    Selection of the reported result
    Some concerns
  3. Home Alone 2020: A First-Person Case Study on Surviving Modern Pandemics and their Aftermath of Illnesses (2026)

    People in the study
    1 in the study
    Dose
    after only two weeks
    Outcome
    brief and remarkable reprieve
    Effect
    better (not tested)
    Risk of bias
    case report or series (JBI checklist for case reports / case series); not rated with RoB 2 or ROBINS-I
  4. Experience of Chronic Fatigue Syndrome Treated with Modified Qinshuyiqi Decoction of Dong Yuan (1997)

    People in the study
    32 in the study
    Dose
    —
    Outcome
    total effective rate
    Effect
    better (not tested)
    Risk of bias
    before-after study without a control group (JBI checklist for quasi-experimental studies); not rated with RoB 2 or ROBINS-I
  5. Successful Treatment of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome with Chronic Febricula Using the Traditional Japanese Medicine Shosaikoto. (2020)

    People in the study
    1 in the study
    Dose
    6.0 g of SST per day
    Outcome
    symptoms did not improve with paroxetine
    Effect
    no clear difference
    Risk of bias
    case report or series (JBI checklist for case reports / case series); not rated with RoB 2 or ROBINS-I
Daily functioning3 studies · 198 people took Chinese, Japanese and Korean herbal medicine Mixed results C
Very low certainty

Why this grade: Mixed results, very low certainty, from randomised trials: one trial of 105 people found no clear difference; a small benefit can't be ruled out; inconsistency: 2 studies without a placebo group found improvement.

The placebo trial127 randomised · 105 analysed · two-month treatment period · daily dose of 9 g, 9 g, 9 g, and 6 g, granules twice daily, once in the morning and once in the evening after meals

No clear difference in daily functioning.

Chinese, Japanese and Korean herbal medicine may make little or no difference to daily functioning in ME/CFS. Little or no difference · low certainty D

  • One trial of 105 people found no clear difference; a small benefit can't be ruled out

Studies with no comparison group2 studies · 135 people with results

Daily functioning improved.

The evidence is very uncertain about the effect of chinese, Japanese and Korean herbal medicine on daily functioning in ME/CFS. Improvement · very low certainty C

  • No control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design)
  • Not all results were tested against chance
See the 3 studies
  1. Sijunzi decoction, a classical Chinese herbal formula, improves fatigue symptoms with changes in gut microbiota in chronic fatigue syndrome: A randomized, double-blind, placebo-controlled, multi-center clinical trial. (2024)

    People in the study
    127 randomised · 105 analysed
    Dose
    daily dose of 9 g, 9 g, 9 g, and 6 g, granules twice daily, once in the morning and once in the evening after meals
    Outcome
    Change of SF36-PF, points, median (IQR) short form-36 physical function subscale
    Effect
    no clear difference
    Risk of bias
    RoB 2: Low
    Randomisation process
    Low
    Deviations from intended interventions
    Low
    Missing outcome data
    Low
    Measurement of the outcome
    Low
    Selection of the reported result
    Low
  2. Home Alone 2020: A First-Person Case Study on Surviving Modern Pandemics and their Aftermath of Illnesses (2026)

    People in the study
    1 in the study
    Dose
    after only two weeks
    Outcome
    wore a dress reserved for swim days only
    Effect
    better (not tested)
    Risk of bias
    case report or series (JBI checklist for case reports / case series); not rated with RoB 2 or ROBINS-I
  3. [Chronic fatigue syndrome--cases in the Kanebo Memorial Hospital]. (1992)

    People in the study
    134 in the study
    Dose
    —
    Outcome
    returned to work or school
    Effect
    better (not tested)
    Risk of bias
    before-after study without a control group (JBI checklist for quasi-experimental studies); not rated with RoB 2 or ROBINS-I
Quality of life2 studies · 111 people took Chinese, Japanese and Korean herbal medicine Little or no difference D
Low certainty

Why this grade: Little or no difference, low certainty, from randomised trials: 201 people in all; a small benefit can't be ruled out; effect size 0.17 (very small).

Placebo trials2 studies · 201 people with results

No clear difference in quality of life.

Chinese, Japanese and Korean herbal medicine may make little or no difference to quality of life in ME/CFS. Little or no difference · low certainty D

  • 201 people in all; a small benefit can't be ruled out
  • Effect size 0.17 (very small)

How big was the difference?

0.17, very small. The effect size compares Chinese, Japanese and Korean herbal medicine with placebo.

See the 2 studies
  1. Sijunzi decoction, a classical Chinese herbal formula, improves fatigue symptoms with changes in gut microbiota in chronic fatigue syndrome: A randomized, double-blind, placebo-controlled, multi-center clinical trial. (2024)

    People in the study
    127 randomised · 105 analysed
    Dose
    daily dose of 9 g, 9 g, 9 g, and 6 g, granules twice daily, once in the morning and once in the evening after meals
    Outcome
    EQ-5D Pareto Classification, n (%) Euroqol Questionnaire
    Effect
    no clear difference
    Risk of bias
    RoB 2: Low
    Randomisation process
    Low
    Deviations from intended interventions
    Low
    Missing outcome data
    Low
    Measurement of the outcome
    Low
    Selection of the reported result
    Low
  2. Effectiveness a herbal medicine (Sipjeondaebo-tang) on adults with chronic fatigue syndrome: A randomized, double-blind, placebo-controlled trial. (2021)

    People in the study
    96 randomised
    Dose
    9 g daily (3 g each time, 3 times a day, before or between meals)
    Outcome
    EQ-5D-5L EuroQoL 5-dimension 5-level questionnaire
    Effect
    no clear difference
    Risk of bias
    RoB 2: Some concerns
    Randomisation process
    Some concerns
    Deviations from intended interventions
    Some concerns
    Missing outcome data
    Low
    Measurement of the outcome
    Low
    Selection of the reported result
    Some concerns

Both together

Daily life and health overall

Overall symptoms1 study · 38 people took Chinese, Japanese and Korean herbal medicine Improvement C
Very low certainty

Why this grade: Improvement, very low certainty, from studies without a control group: no control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design); few people (38 in all); not all results were tested against chance.

Studies with no comparison group38 in the study

Overall symptoms improved.

The evidence is very uncertain about the effect of chinese, Japanese and Korean herbal medicine on overall symptoms in ME/CFS or long COVID. Improvement · very low certainty C

  • No control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design)
  • Few people (38 in all)
  • Not all results were tested against chance
See the 1 study
  1. Effectiveness of Chinese Herbal Treatment for Fibromyalgia and Chronic Fatigue Syndrome (2007)

    People in the study
    38 in the study
    Dose
    —
    Outcome
    “successfully recovered” from fibromyalgia or chronic fatigue syndrome (or both)
    Effect
    better (not tested)
    Risk of bias
    case report or series (JBI checklist for case reports / case series); not rated with RoB 2 or ROBINS-I

Studies of combinations

Outcomes that only studies of Chinese, Japanese and Korean herbal medicine given together with other treatments looked at. Shown, not graded: they can’t tell what Chinese, Japanese and Korean herbal medicine did alone.

Autonomic symptoms Long COVID

Combination: Ethyl loflazepate + Agomelatine (Valdoxan) + Mosapride + Pancreatic enzymes (Creon, Zenpep) + Simethicone (Gas-X) + Tegoprazan + Chinese, Japanese and Korean herbal medicine + Acupuncture + Moxibustion1 in the study

Integrative personalized medicine care for adjustment disorder of a post-COVID-19 patient: A CARE-compliant case report. (2024): autonomic nervous system activity score, better (not tested).

Shown, not counted: Chinese, Japanese and Korean herbal medicine was given together with other treatments.

Fatigue Both together

Combination: Plant-based diet + Vitamin C + CBT and psychotherapy + Exercise (unspecified) + Amitriptyline (Elavil) + hochuekkito1 in the study

A patient who recovered from post-COVID myalgic encephalomyelitis/chronic fatigue syndrome: a case report. (2023): Fatigue level (NRS), better (not tested).

Shown, not counted: Chinese, Japanese and Korean herbal medicine was given together with other treatments.

Cognition (brain fog) Both together

Combination: Plant-based diet + Vitamin C + CBT and psychotherapy + Exercise (unspecified) + Amitriptyline (Elavil) + hochuekkito1 in the study

A patient who recovered from post-COVID myalgic encephalomyelitis/chronic fatigue syndrome: a case report. (2023): TMT-A, better (not tested).

Shown, not counted: Chinese, Japanese and Korean herbal medicine was given together with other treatments.

Autonomic symptoms Both together

Combination: Plant-based diet + Vitamin C + CBT and psychotherapy + Exercise (unspecified) + Amitriptyline (Elavil) + hochuekkito1 in the study

A patient who recovered from post-COVID myalgic encephalomyelitis/chronic fatigue syndrome: a case report. (2023): average heart rate (HR) from 2 to 5 min after standing, better.

Shown, not counted: Chinese, Japanese and Korean herbal medicine was given together with other treatments.

Pain Both together

Combination: Plant-based diet + Vitamin C + CBT and psychotherapy + Exercise (unspecified) + Amitriptyline (Elavil) + hochuekkito1 in the study

A patient who recovered from post-COVID myalgic encephalomyelitis/chronic fatigue syndrome: a case report. (2023): pain, better (not tested).

Shown, not counted: Chinese, Japanese and Korean herbal medicine was given together with other treatments.

Side effects

Stopping because of side effects5 studies
Side effects studies reported4 kinds
Side effects studies reported, and how many studies reported each
Side effectStudies that reported it
Nausea or stomach upset3 studies
Trouble sleeping2 studies
Anxiety or irritability1 study
Headache1 study

Doses studied

What researchers used, as the papers print it; not a recommendation.

  1. 1Start

    0 mg at the start

  2. 2Top dose

    Most often 0 mg (1 of 1 studies)

Doses across 1 study

0 to 0 mg.

Each study’s dose, as printed

Systematic reviews

Reviews pool earlier studies. Each shows when it was published and how far its search went.

Meta-analysisPublished 2025Searched to database inception to February 10, 2023; December 2019 through April 6, 2023

Chinese herbal medicine for dyspnea and persistent symptoms of long COVID: A systematic review and meta-analysis of randomized controlled trials. (2025)

“CHM is associated with a post-treatment clinical reduction in depression and anxiety in long COVID adults, compared to the control”
“CHM is associated with a post-treatment clinical reduction in depression and anxiety in long COVID adults, compared to the control”

All papers

  1. [Compound Ciwujia Granules for chronic fatigue syndrome with syndrome of deficiency of both heart and spleen: a multicenter, randomized, double-blind, double-dummy, positive drug-controlled trial].2026 · placebo trial · 224 randomised · 222 analysed
    Summary

    This multicenter, randomized, double-blind, double-dummy, positive drug-controlled trial evaluated Compound Ciwujia Granules in people with chronic fatigue syndrome with syndrome of deficiency of both heart and spleen. A total of 224 patients were randomized, among whom 222 were included in the full analysis set; 111 were assigned to Compound Ciwujia Granules plus Guipi Granules placebo and 111 to Guipi Granules plus Compound Ciwujia Granules placebo, and the course of treatment lasted for 6 weeks. The primary outcome was the improvement rate measured in the Chalder Fatigue Questionnaire-11(CFQ-11) after 6 weeks of treatment, with secondary outcomes including CFQ-11 score changes and TCM syndrome score changes. After 6 weeks, the CFQ-11 improvement rate was 73.99%(95%CI[69.10%, 78.87%]) in the treatment group versus 52.87%(95%CI[47.99%, 57.76%]) in the control group, with a between-group difference of 21.11%(95%CI[14.19%, 28.04%], P<0.000 1); per-protocol analysis showed a difference of 20.54% (P<0.000 1). The decrease in CFQ-11 scores was -13.81 in the treatment group versus -9.87 in the control group (difference of -3.95, 95%CI[-5.23,-2.66], P<0.000 1), and both physical fatigue and mental fatigue domain scores favored the treatment group after 6 weeks (P<0.000 1). The reduction in TCM syndrome scores was also greater in the treatment group (FAS difference of -1.30, P=0.001 4; PPS difference of -1.14, P=0.005 3). No serious adverse events occurred in either group.

  2. Sijunzi decoction, a classical Chinese herbal formula, improves fatigue symptoms with changes in gut microbiota in chronic fatigue syndrome: A randomized, double-blind, placebo-controlled, multi-center clinical trial.2024 · placebo trial · 127 randomised · 105 analysed
    Summary

    Sijunzi decoction (SJZD) was tested in a multi-center, double-blinded, randomized, placebo-controlled trial in people with chronic fatigue syndrome and spleen deficiency syndrome in China. From June 2020 to July 2021, 127 participants were randomly assigned to SJZD (n = 63) or placebo (n = 64); 105 completed the study. Participants took granules twice daily for a two-month treatment period, with a 1-month follow-up. The primary outcome was change in Chalder fatigue questionnaire (CFQ) scoring. In intention-to-treat analysis, CFQ fell by 6.65 points with SJZD and 5.31 with placebo (difference 1.34, 95% CI -0.65 to 3.33). Per-protocol analysis showed a reduction of 7.82 versus 5.57 points (difference 2.24, 95% CI 0.10 to 4.39; p = 0.043). Response rates were 68.25% (43/63) versus 60.94% (39/64; p = 0.389) in ITT and 81.63% (40/49) versus 66.07% (37/56; p = 0.072) in PP. No significant between-group differences were found in ITT for SF36-PF, spleen deficiency scale, or EQ-VAS; PP EQ-VAS improvement was greater with SJZD (p = 0.009). On EQ-5D, worsening was reported by 10 in SJZD and 11 in placebo. 9 adverse events were reported; 8 were judged unrelated to drug use, and 1 participant in SJZD reported moderate abdominal pain that was relieved after discontinuation. No serious adverse event or abnormal laboratory test was found. Withdrawal/loss to follow-up was 9 with SJZD versus 7 with placebo, and protocol deviation was 5 versus 1.

  3. Effectiveness a herbal medicine (Sipjeondaebo-tang) on adults with chronic fatigue syndrome: A randomized, double-blind, placebo-controlled trial.2021 · placebo trial · 96 randomised
    Summary

    This randomized, double-blind, placebo-controlled trial asked whether Sipjeondaebo-tang (SJDBT) would improve fatigue in adults with chronic fatigue syndrome by US CDC criteria at two Korean medicine hospital sites in the Republic of Korea. Ninety-six eligible participants were randomly allocated 1:1 to SJDBT or placebo; 48 were in the SJDBT group and 48 in the placebo group. Participants received 9 g of SJDBT or placebo granules daily for 8 weeks. The primary outcome was response rate, defined as a Checklist Individual Strength score of 76 or higher. At week 8, response did not significantly differ: 17 (35.4%) in the SJDBT group and 26 (54.2%) in the placebo group (P=0.101). The mean CIS change was not significantly different (P=0.210). VAS fatigue (P=0.001), FSS (P=0.020), and ChFi (P=0.004) scores showed significant improvements with SJDBT; qi deficiency also differed (P=0.043). EQ-5D-5L, happiness, PSQI-K, and blood/yin/yang deficiency did not differ significantly. Six patients were dropped from the SJDBT group and five from the placebo group. Sixteen participants reported adverse events (nine SJDBT, seven placebo), all judged mild and unrelated; no serious adverse events were observed. The authors state the trial primarily failed to show a significant improvement in fatigue severity by the CIS-deprived response rate and that further study is needed.

  4. Effects of Qiye Shen'an Pian Combined with Glutamate and Vitamin B1 on Fatigue State, Immune Function and Quality of Life in Patients with Chronic Fatigue Syndrome.2024 · randomised trial · 106 randomised
    Summary

    This prospective study asked whether adding Qiye Shen'an Pian to glutathione and vitamin B1 affects fatigue, immune function, and quality of life in chronic fatigue syndrome (CFS). It selected 106 CFS patients admitted from June 2021 to June 2023 and, using a simple randomisation method, divided them into two groups. The conventional group received glutathione and vitamin B1; the Qiye Shen'an group received Qiye Shen'an Pian on top of glutathione and vitamin B1 for a continuous period of 8 weeks. The abstract states that immune function-related indexes, free radical metabolism indexes, TCM symptom scores, FS-14 scores, and SPHERE scores were compared, and adverse reactions were recorded and statistically analyzed. For the recorded between-group results, TCM symptom scores, FS-14 scores, and SPHERE scores showed a reduction after treatment in both groups, with a more substantial decrease in the Qiye Shen'an group (P < .05). No counts for adverse reactions, withdrawals, or patients who worsened are reported in the abstract. The co-intervention with vitamin B1 is named inconsistently: glutathione in the methods, glutamate in the title, ghrelin in the objective, and glutamine in one conclusion sentence. The authors state no limitations in the abstract.

  5. Selective serotonin reuptake inhibitor combined with dengzhanshengmai capsule improves the fatigue symptoms: a 12-week open-label pilot study.2015 · randomised trial · 268 randomised · 223 analysed
    Summary

    This 12-week open-label randomised trial compared SSRI alone with SSRI plus Dengzhanshengmai capsule in adults with chronic fatigue syndrome at three centres in Zhejiang, China, recruiting from September 2012 to October 2014. A total of 268 patients were randomly assigned: 134 to SSRI (Seroxat 10-30 mg/day or Zoloft 25-100 mg/day or Citalopram 10-30 mg/day for the first 4 weeks, then standard maintenance) and 134 to SSRI plus Dengzhanshengmai 1.08 g/day for 12 weeks. At the end, 223 patients completed the trial. The study measured MFI-20 fatigue subscales and Hospital Anxiety and Depression Scale scores and monitored adverse events. The paper reports greater improvement in the combined group for general fatigue (0.8±0.6 vs. 1.3±0.7), physical fatigue (0.6±0.3 vs. 1.0±0.4) and reduced activity (1.0±0.5 vs. 1.3±0.6) since the 2nd week (P<0.01), and for reduced motivation (2.1±0.8 vs. 2.4±1.0) since the 8th week (P<0.01). Mental fatigue and HAD scores showed no significant difference between groups (P>0.05). Drop-out was 15.7% with SSRI and 18.0% with combined therapy, with no significant difference stated; 45 patients (21 vs. 24) did not complete due to drug unavailability. The text reports 21 vs. 24 patients with mild to moderate adverse events, while Table 3 reports total adverse events 56 (41.8) vs. 55 (41.0); no serious adverse events or death were found. Hypertension was 5.8% vs. 1.5%, with P = 0.08 in the text and P = 0.05 in Table 3. The authors state limitations including a short-term, nondouble-blind follow-up.

  6. [Effect of lixu jieyu recipe in treating 75 patients with chronic fatigue syndrome].2009 · randomised trial · 75 randomised
    Summary

    This randomized study enrolled Seventy-five CFS patients meeting the inclusive criteria from March 2007 to April 2008. The 40 patients in the treated group received Lixu Jieyu Recipe orally, 100 mL twice a day, made from milkvetch root 30 g, kudzuvine root 30 g, asiabell root 15 g, red sage root 10 g, aizoon stonecrop 15 g, epimeddium herb 10 g, curcuma root 10 g, and grassleaved sweetflag rhizome 10 g in 200 mL decoction. The 35 patients in the control group received vitamin B tablets 10 mg twice a day, adenosine triphsphate (ATP) 20 mg thrice a day and Oryzanol tablets 20 mg thrice a day. Treatment lasted 3 months. After treatment, the difference in scores of fatigue symptoms between the two groups was significant (P < 0.01). In the treated group, scores of various SCL-90 factors and the total score significantly reduced after treatment (P < 0.01). Immunoglobulins were unchanged after treatment in both groups (P > 0.05) and showed no significant difference between groups. Th and Ts cells increased and CD4/CD8 ratio decreased in both groups after treatment (P < 0.05), with more significant improvement in the treated group and a significant between-group difference after treatment (P < 0.05). Side effects and withdrawals were not reported.

  7. Clinical Observation of the Treatment of 63 Cases of Chronic Fatigue Syndrome by Using Shengmai Decoction in Combination with Suefu Zhuyu Decoction2006 · randomised trial · 125 randomised
    Summary

    This abstract-only report describes a randomised comparison in 125 patients with chronic fatigue syndrome (CFS as printed); the setting and number of patients per arm were not reported. Participants were randomly divided into a treat group and a control group. The treat group received Shengmai Decoction combined with Suefu Zhuyu Decoction. The control group received Vitc, VitBco, ATP and Oryzanol. Both groups had a course of 4 weeks. The outcome reported was clinical curative effects, specifically the total effective rate. The total effective rate was 80.95% in the treating group and 56.90% in the control group; the abstract states there was a significant difference between the two rates (P0.05). No other outcomes, adverse events, harms, withdrawals, or follow-up beyond the 4-week course were reported in the text provided. The abstract does not report the randomisation method, blinding, allocation concealment, missing data, funding, or conflicts of interest. The authors conclude that Shengmai Decoction and Suefu Zhuyu Decoction has better therapeutic effect on CFS. They do not state any limitations in the abstract.

  8. Clinical Observation of Chronic Fatigue Syndrome Treated by Chinese Medicine in Hong Kong2005 · randomised trial · 56 randomised
    Summary

    The abstract describes a randomized study in Hong Kong that aimed to observe the clinical efficacy of Chinese medicine in improving chronic fatigue syndrome (CFS). It reports that 56 subjects were randomized into two groups: a treatment group of 31 cases given “Xianshen Decoction” and a control group of 25 cases given vitamin A Z, with a course of 30 days. The abstract states that clinical symptom scores and effective rate were observed in both groups. In the treatment group, it reports a significant difference in clinical symptom scores between before and after treatment (P 0 01). For the outcome printed as “effective rate,” it reports 90.32% in the treatment group, higher than 8.00% in control (P 0.01). The abstract states that Chinese medicine can greatly improve the clinical symptoms of CFS patients. It does not report the number analysed, any side effects, any withdrawals, or limitations. The abstract does not state limitations.

  9. A Cohort Study on Traditional Chinese Medicine Syndrome Differentiation-based Treatment for Post-COVID-19 Syndrome2026 · compared with another group · 434 in the study · 188 with outcome data
    Summary

    This cohort study examined traditional Chinese medicine (TCM) syndrome differentiation-based treatment for post-COVID-19 syndrome in a single-center outpatient setting between May 2023 and December 2024. A total of 434 patients were enrolled: 128 in the treatment group and 306 in the control group. The treatment group received TCM plus conventional Western medicine and lifestyle intervention; the control group received conventional Western medicine and lifestyle intervention. Treatment lasted seven consecutive days, with outcomes at Day 7. After 1:1 propensity score matching, 94 matched pairs were analysed. The primary outcome, total effective rate of TCM symptom improvement, was 30.85% (29/94) in the treatment group and 17.02% (16/94) in the control group (OR = 2.17, 95% CI: 1.09–4.35, P = 0.003). Median change in TCM syndrome score was 3.00 (0.25, 5.75) in the treatment group and 1.00 (0.00, 4.00) in the control group (P = 0.009). Median change in SF-36 standardized total score was 2.00 (−2.30, 5.00) in the treatment group and 0.00 (−2.75, 4.00) in the control group, with no significant intergroup difference (P = 0.268). No cure cases were found in either group. The three TCM syndrome types in the treatment group all showed symptomatic improvement, with the highest effective rate in Lung–Spleen Qi Deficiency Syndrome (32.14%). No adverse events were reported in either group during the 7-day treatment period.

  10. Impact of traditional Chinese medicine on the prognosis of COVID-19 in cancer patients: a questionnaire-based survey.2025 · compared with another group · 1,032 in the study · 996 with outcome data
    Summary

    An anonymous online cross-sectional survey invited 1,032 cancer patients diagnosed with COVID-19; 996 completed it, with 607 in the TCM group and 389 in the non-TCM group. TCM participants had medical records indicating at least 1-month of TCM use; non-TCM participants had never used TCM. The paper reports post-COVID symptom comparisons at 3 months post-infection in table headings for TCM (N = 460) and non-TCM (N = 327), while elsewhere describing 607 TCM and 389 non-TCM cancer patients with COVID-19, a source conflict. The non-TCM group had a higher infection rate (84.1% vs. 75.8%, p = 0.002). At 3 months, 98.0% of the TCM group reported no fatigue versus 91.7% in the non-TCM group (p < 0.001), and 98.7% reported no sleep difficulties versus 88.7% (p < 0.001). Median infection duration was 7 days in both groups (p = 0.178); median body temperature was 38.2 °C in TCM and 38.3 °C in non-TCM (p = 0.123); median duration of fever was 2 days in both groups (p = 0.003). There was no difference in hospitalizations due to COVID-19 infection (p = 0.18). No harms or side effects were reported for either group.

  11. Effectiveness of Five-Element Regulatory Therapy for post-COVID syndrome: a retrospective cohort study.2025 · compared with another group · 127 in the study
    Summary

    This retrospective cohort study examined Five-Element Regulation Therapy (FERT), a Traditional Chinese medicine intervention, for post-COVID syndrome in patients receiving outpatient care at the Department of Traditional Chinese Medicine, Peking University Third Hospital, Beijing, between January 1, 2023 and May 31, 2023. The study enrolled 127 patients: 81 received FERT herbal formulations and 46 received conventional TCM therapy. Both groups maintained treatment for 2 weeks and were followed at 2-weeks post-treatment. The primary outcomes were clinical cure rate and clinical response rate at 2 weeks after treatment initiation. The paper reports a clinical cure rate of 61.7% in the FERT group and 21.7% in the control group (p < 0.001), and a clinical response rate of 88.9% in the FERT group and 67.4% in the control group (p < 0.01). Dropout cases were 4 in the FERT group and 3 in the control group. Side effects were not reported. The authors state that the study is retrospective and non-randomised, with possible selection bias and confounding, a small sample size, no long-term follow-up beyond 2 weeks, a single hospital population, subjective symptom endpoints, and no placebo control.

  12. Herbal medicines for long COVID: A phase 2 pilot clinical study.2024 · compared with another group · 45 in the study
    Summary

    This prospective pilot study at Kyung Hee University Korean Medicine Hospital in Seoul enrolled 45 patients with long COVID fatigue or cognitive dysfunction. Participants received one of three herbal medicines for 12 weeks, with follow-up assessed up to 36 weeks after participation: Bojungikgi-tang (BIT), Kyungok-go (KOG), or Cheonwangbosim-dan (CBD), 15 in each group. There was no control group, and randomization, allocation concealment, and blinding were not implemented. For fatigue, treatment success on a visual analog scale was 12 (80) in BIT, 8 (53.33) in KOG, and 7 (46.67) in CBD (p = 0.1431). For cognitive dysfunction, treatment success was 6 (40), 7 (46.67), and 2 (13.33), respectively (p = 0.1225). Among included participants, 14 (31 %) dropped out. Adverse events were reported by 10 (22.22 %) participants overall: 5 (33.33) in BIT, 1 (6.67) in KOG, and 4 (26.67) in CBD (p = 0.2805). All adverse events were mild and none were found to be causally related to the medication; no withdrawals were linked to adverse events from the administered drug.

  13. Herbal medicine (Kyungok-go) for fatigue in Long COVID patients: A prospective multicenter pilot study.2026 · no comparison group · 100 in the study
    Summary

    This multicenter, prospective, single-group pilot study assessed Kyungok-go for Long COVID-related fatigue. It enrolled 100 participants with fatigue at least 12 weeks after COVID-19 diagnosis at two Korean Medicine hospitals in Seoul and Busan. Participants received Kyungok-go 22.5 g twice daily between meals for 12 weeks; there was no control group, and outcomes were compared before and after treatment. The primary outcome was the Fatigue Severity Scale (FSS). Secondary measures included fatigue VAS, Chalder Fatigue Scale (ChFS), sleep quality, depressive symptoms, cognitive and physical function, quality of life, adherence, and adverse events. After treatment, FSS changed by -2.1 (95% CI -2.4, -1.9), VAS by -35.6 (-39.7, -31.4), and ChFS total by -29.1 (-32.3, -25.9). PSQI-K changed by -4.0 (-4.8, -3.2), BDI by -8.1 (-9.6, -6.7), and EQ-5D-5L by 0.1 (-0.1, 0.1). DF and DB tests showed no significant changes; CNT showed no significant improvement except in the trail-making test; physical performance did not change significantly. Six participants dropped out due to unexpected illnesses (n = 3) or voluntary withdrawal (n = 3). Medication adherence ranged from 97.5% to 99.7%. Most AEs were mild, with two moderate AEs (shoulder pain and tendinitis) and one severe AE (osteoporosis); all three moderate to severe AEs were determined unrelated to the herbal medicine. Five abnormal BUN levels, two creatinine values below normal range, one AST outside normal range, three elevated ALT levels, and 14 ECG abnormal findings were observed; no adverse drug reactions were judged related to Kyungok-go.

  14. Weight Change After Korean Medicine Weight Management Treatment Combined with a Low-Carbohydrate Diet in Patients with Post-COVID-19 Condition: A Retrospective Multicenter Observational Study2026 · no comparison group · 20 in the study · 11 started · 11 with outcome data
    Summary

    This retrospective multicenter observational study used electronic medical records from eight Korean medicine clinics to describe weight change after Korean medicine weight management treatment combined with a low-carbohydrate diet in patients with post-COVID-19 condition. Records were searched from 1 Jan 2024 to 31 Oct 2025; 20 patients were identified, 9 were excluded because no follow-up data after treatment were available, and 11 were analysed. The mean follow-up from first to last visit was 185.0±138.5 (33–478) days; treatment duration was not reported. Treatment included an ephedra-containing solid preparation (Daeat-dan; ephedra content per pack 2.5, 3.2, 3.9, 4.6, 5.3, or 6.0 g), decoction in 6 of 11 (54.5%), a low-carbohydrate diet (about 50 g carbohydrate/day advised), and pharmacopuncture or device treatment in some patients. There was no comparison group. Body weight decreased from 69.66±16.50 kg to 64.14±15.55 kg (p=0.005), BFM from 27.03±8.72 kg to 22.66±6.58 kg (p=0.024), and BMI from 27.07±4.99 kg/m² to 24.85±4.08 kg/m² (p=0.007). SMM changed from 23.09±6.58 kg to 22.47±6.41 kg (p=0.145) and %BF from 38.41±8.13% to 35.22±5.66% (p=0.067), both not statistically significant. In 10 patients with paired measurements, sBP, dBP and HR showed no statistically significant change. Mild adverse events occurred in 5 of 11 patients (45.5%); 6 events (constipation 2, nausea 2, headache 1, insomnia 1) were all Grade 1, with no severe adverse events. Table 6 lists a total of 6 (54.5%).

  15. Course of General Fatigue in Patients with Post-COVID-19 Conditions Who Were Prescribed Hochuekkito: A Single-Center Exploratory Pilot Study.2025 · no comparison group · 20 in the study · 13 with outcome data
    Summary

    This single-arm exploratory pilot study enrolled 20 patients with long COVID or PCC and general fatigue at Okayama University Hospital from September to December 2023. All participants were prescribed hochuekkito 7.5 g/day for 8 weeks; there was no comparison group. The Japanese version of the fatigue assessment scale (FAS) was measured. Of 20 patients, 13 had baseline and week 8 data and were analysed; seven subjects with missing baseline or week 8 data were excluded. FAS scores decreased from 35.9 (SD: 5.9) at the initial visit to 31.2 (SD: 9.4) after 8 weeks (difference of 4.7: 95% CI: 0.5–8.9). All patients were treated as outpatients and no patients required hospitalization. The authors state limitations including a single referral clinic, small sample size, confounding, missing FAS data, possible natural improvement, changes to Kampo prescriptions during the 8 weeks, and some cases more than one year from symptom onset.

  16. Effectiveness of Japanese traditional medicine (Kamikihito and Saikokeishito) for treating long COVID: a prospective observational study.2025 · no comparison group · 242 in the study · 112 started · 112 with outcome data
    Summary

    This single-center prospective observational study asked whether Japanese traditional medicine (JTM) affects quality of life in long COVID. Of 242 patients visiting a general medicine outpatient department between March 2021 and August 2024, 112 were analyzed; symptoms had persisted beyond 28 days from COVID-19 onset. Treatment was decided by the attending physician; 101 patients received JTM, including 20 given kamikihito plus saikokeishito, and 11 received Western monotherapy. The paper states there was no control group. Patients completed EQ-5D-5L and EQ-VAS at baseline and 3 months. For all 112, median HR-QOL rose from 0.711 to 0.833 (p < 0.0001); patients achieving the Japanese average HR-QOL increased from 8 (7.1%) to 23 (20.4%) (p = 0.004); EQ-VAS changed by 10 (−5–20) (p < 0.0001). Among 56 patients with brain fog, HR-QOL rose from 0.677 to 0.750 (p = 0.005). Kamikihito/saikokeishito combination use was associated with HR-QOL improvement: odds ratio 5.4 (95% CI 1.4–30.1, p = 0.03) in all patients and 6.1 (95% CI 1.6–30.8, p = 0.01) in brain fog patients. Side effects and withdrawals were not reported in this study. The authors state that natural recovery cannot be excluded, that the brain fog group was limited, and that KKT/SAKT effects were not isolated from Western medicine.

  17. Evaluating the efficacy of traditional Chinese medicine in treating COVID-19 and long-COVID symptoms: a combined meta-analysis and retrospective study2025 · no comparison group · 1,331 in the study
    Summary

    This retrospective study examined whether outcomes of Traditional Chinese Medicine (TCM) treatment in Long COVID could be predicted from patient data. It included 1,331 Long COVID patients treated with TCM at hospitals in Zhejiang, China. All received a sequential TCM therapy over a 14-day period: CRPRF and YTRF herbal formulas, with the herbal medicine decocted into 150 ml per packet and one packet taken each morning and evening, plus thumb-tack needle acupuncture. There was no separate comparison group; the study classified patients by outcome and built prediction models. Improvement was defined as improvement in two or more clinical symptoms or a TCM syndrome score improvement of at least 2 points. The paper reports 1,155 patients met this improvement definition and 176 did not. It also reports that patients with a lower lymphocyte ratio responded better to TCM treatment than those with a higher ratio, and that patients with chest tightness and aversion to cold showed a better response than those without these symptoms. No side-effect data were reported for this study, and withdrawals or worsening were not reported. The authors state limits: all case data came from Zhejiang Province, China; database-derived cases may contain subjective biases; treatment failures were relatively few; some subjective indicators were hard to categorize; and inflammatory, immunological, and imaging-related parameters were limited.

  18. Evaluating myelophil, a 30% ethanol extract of Astragalus membranaceus and Salvia miltiorrhiza, for alleviating fatigue in long COVID: a real-world observational study.2024 · no comparison group · 50 in the study · 49 started · 49 with outcome data
    Summary

    This prospective single-arm observational study enrolled 50 people with Long COVID who had significant fatigue or brain fog at Daejeon Korean Medicine Hospital; 49 were included in the intention-to-treat analysis. Participants took Myelophil (MYP), a 30% ethanol extract of Astragalus membranaceus and Salvia miltiorrhiza, orally at 2,000 mg daily for 4 weeks. There was no control group. The study measured mKCFQ11, MFI-20, Fatigue VAS, Brain Fog VAS, and SF-12. After 4 weeks of MYP administration, mKCFQ11 changed from 66.9 ± 11.7 to 34.8 ± 17.1 (p < 0.001); physical fatigue from 45.1 ± 6.6 to 23.8 ± 11.3 and mental fatigue from 21.9 ± 6.6 to 11.1 ± 7.1 (p < 0.001 for both). MFI-20 shifted from 64.8 ± 9.8 to 49.3 ± 10.8, Fatigue VAS from 7.4 ± 1.0 to 3.4 ± 1.9, Brain Fog VAS from 6.3 ± 1.5 to 3.0 ± 1.9, and SF-12 from 53.3 ± 14.9 to 78.6 ± 14.3. One participant (2.04%) experienced mild indigestion but recovered without any specific treatment; no other adverse reactions, including liver and kidney function in blood tests, were observed (data not shown). One female participant withdrew due to personal circumstances before the drug administration began. The authors state limitations including no control group, open-label design, limited participant pool, and a 4-week timeframe.

  19. Therapie von Long-Covid-Syndromen mit chinesischer Arzneimitteltherapie im Erwachsenen‑, Kindes- und Jugendalter Chinese herbal medicine in the therapy of post-covid syndromes in adults, children and adolescents2021 · no comparison group
  20. Experience of Chronic Fatigue Syndrome Treated with Modified Qinshuyiqi Decoction of Dong Yuan1997 · no comparison group · 32 in the study
    Summary

    This abstract-only report describes 32 cases of Chronic Fatigue Syndrome (CFS) treated with modified Qinshuyiqi decoction of Dong yuan. No study design, setting, treatment duration, or comparison group is reported; the text states no randomisation and no control arm. The author reports obvious therapeutic effects on fatigue, low fever, ache, narcolepsy, swelling of lymph and sweating, and states that the total effective rate was over 80%. The abstract does not report how many participants were analysed, how long they were followed, how the decoction was dosed or scheduled, or how the symptoms and total effective rate were measured. It gives no p-values, confidence intervals, or significance statements for the symptom improvements or the total effective rate. Harms, side effects, and withdrawals are not reported. The abstract does not compare the decoction with placebo or another treatment and does not report any participant-level counts for the symptoms listed. The text does not state limitations.

  21. [Chronic fatigue syndrome--cases in the Kanebo Memorial Hospital].1992 · no comparison group · 134 in the study
  22. Integrative strategy for Long COVID neuropsychiatric symptoms: A case report on Kamikihito and Bupleurum-Scutellaria formulas guided by pharmacological rationale.2026 · case report · 1 in the study
    Summary

    This case report described one male in his fifties who presented to a Department of Kampo Medicine five months after COVID-19 with brain fog, anxiety, headache, fatigue, and palpitations. He received Kampo pharmacotherapy: Kamikihito extract granules 7.5 g/day initially; Saireito extract granules 7.5 g/day added; and Saikokaryukotsuboreito extract granules 2.5 g/day, morning dose, added. All prescriptions were discontinued 11 months after the initial visit, and follow-up was concluded at 12 months. There was no comparison group; the paper described a single case report. Outcomes included EQ-5D-5L HR-QOL, EQ-VAS, SF-12 MCS, RCS, and PCS, the Brain Fog Score, insomnia, all symptoms, difficulties in daily living, and return to work. EQ-5D-5L was 0.696 at baseline, 0.839 at three months, and 0.878 at the final visit; EQ-VAS was 50, 70, and 75. SF-12 MCS was 38.5, 46.7, and 56.7; RCS was 34.6, 41.8, and 51.0; PCS was 55.0 at baseline and 53.0 at the final visit. BFS was 6 at baseline and 3 at the final visit. Insomnia improved at two weeks; all symptoms showed an improving trend at one month; difficulties in daily living resolved and he returned to work at two and a half months. Blood tests showed no findings suggestive of adverse effects; serum potassium levels and blood pressure remained normal. The patient did not wish to continue.

  23. Potential application of brain-gut axis-based treatments in Long COVID and ME/CFS: a case-based systematic review.2026 · case report · 1 in the study
    Summary

    This case report and literature review describes one 33-year-old man with post-COVID ME/CFS admitted to Jaseng Hospital of Korean Medicine. He received vagal reflex stimulation via electroacupuncture of the deep peroneal nerve for 12 weeks (once daily for three consecutive weeks during hospitalization, then tapering). There was no comparison group. Fatigue was assessed with the Multidimensional Fatigue Inventory (total score 20–100) at baseline and at 4, 8 and 12 weeks, and flu-like symptom duration was self-recorded daily. Total MFI score declined from 71 to 31 (a reduction of more than 50%). General fatigue and reduced activity each fell −9 points; mental fatigue improved 63.6% (11 to 4) and reduced motivation 61.5% (13 to 5). General fatigue fell below the cut-off (< 13) at week 8 and reduced activity reached the threshold (< 10) at week 12. Daily flu-like symptom duration decreased from 557.1 ± 51.2 to 17.1 ± 15.8 min. Fluctuations at weeks 4 (282.9 ± 126.0 min) and 8 (285.7 ± 140.5 min) reflected transient, single-day symptom flares. No adverse events were observed. The authors state that lack of follow-up data precluded assessment of treatment durability, objective measures were not obtained, and few RCTs with small samples were included.

  24. Home Alone 2020: A First-Person Case Study on Surviving Modern Pandemics and their Aftermath of Illnesses2026 · case report · 1 in the study
    Summary

    This single-person case study reports the author’s ME/CFS course from 2010 to 2026, with no comparison group and no blinding. Treatments included Valtrex (valacyclovir) eight tablets a day throughout 2016; Xue-Fu-Zhu-Yu-Tang; weekly acupuncture for eighteen months; Lomatium dissectum started in July 2019 and taken daily; Oxymatrine (or Equilibrant); X39 phototherapy patches since summer 2020; concentrated oxygen ninety minutes a day over six months; and xylitol nasal spray since winter 2020. The author reports using laboratory results and her own observations, not a validated symptom scale. After only two weeks of Chinese herbs she had a brief and remarkable reprieve. After six weeks of acupuncture she went, in her case, from being bedridden and dying to dancing; after six months of weekly acupuncture she survived a short flight and reported dancing like a twenty year old. Weekly acupuncture over eighteen months revived her, but did not kill the viruses. Lomatium produced an immediate emotional response called a pathogen “die-off” and left her feeling lighter in body and spirit. Patches restored energy; concentrated oxygen coincided with improvements in pre-diabetes, allergies, arthrosis and breathing. Valtrex viral loads never dropped, and eight tablets a day made her very ill. Harms included not tolerating certain herbs or tablets and medication overload, elimination and withdrawal; she never had the Lomatium rash. The authors state the case cannot show causation.

  25. Chinese Herbal Treatment For Long COVID Brain Fog, A Case Report2023 · case report · 1 in the study
    Summary

    This case report described one 67-year-old White female with long COVID brain fog. In mid-September 2022 she sought Chinese herbal treatment after continuous brain fog forced her to take a leave of absence from work. She was advised to take 5 g of a granule formula once in the morning and once at night. The first formula was taken for 15 days, after which the patient started feeling better and could start doing regular daily tasks; the second formula was taken until the beginning of December. There was no comparison group and no randomisation. The report summarises how her brain fog improved over time and states that she stopped taking the herbs once she felt her brain fog lift. She had not experienced any brain fog for the four months between the end of treatment and the writing of the case report. Harms were not reported, and withdrawals for harms were not reported. The authors state that further study would be required to determine whether this treatment would work in other instances.

  26. Late-Onset Hypogonadism in a Male Patient with Long COVID Diagnosed by Exclusion of ME/CFS.2022 · case report · 1 in the study
    Summary

    This case report described one 36-year-old man who developed persistent general fatigue after SARS-CoV-2 infection and was diagnosed with late-onset hypogonadism (LOH) after ME/CFS was excluded. He was referred from an online clinic to the authors’ COVID-19 aftercare clinic 99 days after the initial symptoms. He received hochuekkito, a Japanese traditional medicine (Kampo medicine); after about 2 months, juzentaihoto was started. There was no comparison group. The report states that after treatment initiation his symptoms and AMS score were noticeably improved; his baseline AMS score was 44 out of 85. Follow-up was reported at about one month (phase 2) and six months (phase 3) after the first examination. Side effects and withdrawals were not reported. The authors conclude that LOH syndrome should be distinguished from ME/CFS in patients with persistent malaise and that Kampo medicine might be a treatment option for patients with LOH after COVID-19 infection. No limitations were stated.

  27. Effects of Korean Medicine Treatment in Post-acute COVID-19 Syndrome: A Retrospective Case Series of 15 Patients2022 · case report · 15 in the study
    Summary

    This retrospective case series described clinical features and before/after outcomes of Korean medicine treatment for post-acute COVID-19 syndrome. It included 15 patients who visited the outpatient Allergy, Immune, and Respiratory System Department at Kyung Hee University Korean Medicine Hospital from January 10, 2021 to April 10, 2022. Herbal medicine was prescribed for all 15 patients; acupuncture and cupping were performed in 4 patients (26.7%) each, and electroacupuncture in 1 patient (6.7%). Treatment lasted a minimum of 26 days, a maximum of 148 days, and an average of 77.9±31.1 days. There was no comparison group. Outcomes were NRS, mMRC, LCQ, QOL-VAS, and PCFS before and after treatment. NRS was available in 5 patients (33.3%), and all decreased; mMRC in 3 (20%), all to 0; LCQ in 4 (26.7%), all increased. QOL-VAS was available in 6 (40%): 2 were unchanged and 4 increased. PCFS was available in all 15: 2 were unchanged and 13 decreased. Adverse events occurred in 2 patients (13.3%): 1 had dyspepsia, and 1 had dyspepsia and headache; events were mild, and both improved after herbal medicine dose reduction.

  28. Case Report: Acupuncture is an effective treatment for olfactory dysfunction in the post COVID-19 condition.2022 · case report · 2 in the study
    Summary

    This case report describes two patients with post COVID-19 condition and olfactory dysfunction who were referred to the authors' department. There was no comparison group. Both received acupuncture treatment at LI20 plus systemic points, with needles 30 mm long and 0.16 mm in diameter inserted about 10 mm deep, scheduled 1–2 times a week. Both also received Kampo prescriptions (Kamikihito in case 1; Ninjin'yoeito in case 2). Olfactory dysfunction was rated on an NRS from 0 to 10. In case 1, the NRS decreased from 10 to 6 immediately after acupuncture; after a total of eight sessions the patient still had an NRS score of 9. After LI20 was added at the ninth session, the NRS was reduced to 4 immediately after treatment and maintained at 7 after 2–3 days. In case 2, the baseline NRS was 3; after the second and third treatments there was a rapid reduction to an NRS score of 0, and later the patient's olfactory dysfunction eased to an NRS score of 0–1. The abstract reports improvement lasting 2–4 days; case 1's reduction lasted 2–3 days before flare-up, and case 2's lasted 3–4 days. Malaise also improved but flared the next day. No adverse reactions were observed.

  29. Long COVID-associated Brain Fog and Therapeutic Intervention Using Repetitive Transcranial Magnetic Stimulation(rTMS)2022 · case report · 1 in the study
    Summary

    This is a single case report (症例提示) of one patient with long COVID-associated brain fog seen at the author's post-COVID outpatient clinic in Japan. The patient was given high-frequency rTMS at 10 Hz, 1,200 pulses to each target site (bilateral occipital lobes and the right dlPFC), at an intensity of 90% of the minimum motor threshold required for upper-limb motor area stimulation, once weekly for 10 consecutive sessions. There was no comparison group and no randomisation. Brain fog improved markedly immediately after the first rTMS session. At the end of the 10th session, memory-related failures slightly remained while visuospatial failures were absent; the patient could read without difficulty and join conversations without stagnation, the planned demotion was withdrawn and he returned to full work. At follow-up 1 month after the end of rTMS there was no re-exacerbation of symptoms; fatigue was not entirely absent but recovered with one night's sleep, and clock drawing was correct. No adverse events occurred during the rTMS period. The authors state that many questions remain about the specific method — frequency, stimulation intensity, number of sessions and especially the stimulation site — and that their method is not considered optimal.

  30. Successful Treatment of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome with Chronic Febricula Using the Traditional Japanese Medicine Shosaikoto.2020 · case report · 1 in the study
    Summary

    This case report describes one 14-year-old girl with ME/CFS and chronic intermittent febricula who had experienced fatigue, febricula and social withdrawal for 20 months and was referred to the authors' department. There was no comparison group; changes are reported before versus after treatment in the same patient. She was prescribed shosaikoto 6.0 g per day; 6.0 g of orengedokuto was later added to SST for low-grade fever and fatigue. Six weeks after the first consultation, ogikenchuto 18 g/day replaced OGT for appetite loss and fatigue, and tokishakuyakusan 5.0 g daily later replaced SST. A psychiatrist prescribed paroxetine for five weeks, but her symptoms did not improve and it was tapered and discontinued. The performance status score was 6 at baseline and decreased to grade 1 when she returned to school. The authors report alleviation of several symptoms two weeks later, resolution of malaise, intermittent fever and sleep disturbance at six weeks, mostly resolved ME/CFS symptoms at seven months, and almost symptom-free status sixteen months after the first consultation, when all Kampo treatments were terminated. No adverse effects of Kampo treatment were observed. The authors state no limitations.

  31. [Clinical research of auricular gold-needle therapy in treatment of chronic fatigue syndrome of qi deficiency constitution].2019 · case report · 120 in the study
    Summary

    This randomised study enrolled 120 patients with chronic fatigue syndrome of qi deficiency constitution, with 40 cases in each of three treatment groups: auricular gold-needle therapy, auricular point pressure therapy, and a Chinese herb group. A separate health control group of 40 cases received no intervention. In the gold-needle group, a gold needle stimulated auricular points on one side and cowherb seed pressure was used on the other side; the pressure group received cowherb seed pressure on one side only. Both had treatment once a week, 4 treatments as one course, with 3 consecutive courses required. The herb group took buzhong yiqi wan orally, 6 g twice a day, with 1 month as one session and 3 consecutive sessions required. Clinical symptom score and serum IgA, IgG and IgM were observed before and after treatment, and therapeutic effects were evaluated. The total effective rate was 90.0% (36/40) in the gold-needle group, 80.0% (32/40) in the pressure group and 82.5% (33/40) in the herb group; the abstract reports the gold-needle rate as better than the other two. Harms and withdrawals are not reported. No limitations are stated in the abstract.

  32. Case Report of Chronic Fatigue Syndrome Treated with Salt-Indirect Moxibustion2012 · case report · 1 in the study
    Summary

    This case report describes one 53-year-old man with chronic fatigue syndrome (CFS) who visited an Oriental hospital with chronic and severe fatigue. He was treated as an outpatient every day for 14 days with indirect moxibustion on three acupoints, KD1, CV4 and CV8, for 30 minutes daily; the moxa corn consisted of 3.5 g of wormwood fiber. He also received acupuncture (mainly at HT7, LI4, SP3) and a herbal drug (Myelophil, twice per day). There was no comparison group; outcomes were self-reported before and after treatment. VAS and NRS were recorded on Day 1, Day 7 and Day 14. The abstract and results text report VAS and NRS changed from 8.5 and 70 to 3.5 and 35, respectively; Table 1 and the Discussion print the final VAS as 3.3. Table 1 shows NRS 70 on Day 1, 53 on Day 7, and 35 on Day 14, and VAS 8.5, 6.1, and 3.3. The report states fatigue feeling and related-symptoms were radically reduced by 14-day treatment, and other physical and mental activities improved. Harms, worsening, and withdrawals were not reported. The authors state that further study needs to verify the therapeutic effects of moxibustion on CFS and its mechanisms using more subjects, and that this case study didn’t measure biomarkers for oxidative stress and antioxidants.

  33. Effectiveness of Chinese Herbal Treatment for Fibromyalgia and Chronic Fatigue Syndrome2007 · case report · 38 in the study
    Summary

    This case series reports on 38 patients presenting for treatment to J. Gilbert. Of these, 22 had a prior diagnosis of chronic fatigue syndrome, twenty patients had a prior diagnosis of fibromyalgia, and 4 patients had a prior diagnosis of both syndromes. All received customized Chinese herbal treatment, as prescribed by J. Gilbert. The average length of treatment was 10.3 months. There was no comparison group; the paper describes the design as a case series. The outcome was “successfully recovered” from fibromyalgia or chronic fatigue syndrome (or both). Recovery required both the patient and practitioner to agree on return to previous functioning, freedom from persistent symptoms associated with the conditions, and being off medications or dietary supplements started specifically for the conditions or associated symptoms. No patients were excluded. Twenty-eight of the 38 patients in this case series “successfully recovered,” showing an effectiveness rate of 73.7 percent. The text does not report side effects, worsening, or withdrawals; no harms are reported. The text does not state limitations. The authors conclude that customized Chinese herbal treatment, as prescribed by J. Gilbert, has demonstrated recovery from fibromyalgia and chronic fatigue syndrome to previous levels of health.

  34. Chronic fatigue syndrome and women: can therapy help?1992 · case report · 1 in the study
    Summary

    This paper reports a case study of one woman, “Claire,” with chronic fatigue syndrome and Epstein-Barr virus, in psychotherapy with the author. She received insight-oriented psychotherapy; treatment lasted three years. There was no comparison group. The paper reports that psychotherapy helped Claire. It reports that psychotherapy apparently helped her alleviate longstanding symptoms of depression, that her emotional life became calmer, more manageable, and more satisfying, that she had more insight into her previous needs to achieve professionally, and that she was beginning to see her life as approximating “normal” again in terms of health and lack of symptoms. For health over the first 24 months of treatment, the paper reports that her health would appear to improve and then all of a sudden deteriorate. Reported harms include that her health deteriorated during treatment to the point that she felt she had to quit her job, and that she would have a week of overwhelming fatigue and then need complete bedrest. The authors state that it cannot be generalized that insight therapy can help all victims of chronic fatigue syndrome.

  35. Factors involved in the improvement of prolonged symptoms in patients with COVID-19 treated with Japanese traditional (Kampo) medicine: A single-center, prospective, observational study.2026 · combination: given with other treatments · 128 in the study · 114 with outcome data
    Summary

    This single-center, prospective, observational study in Japan enrolled 128 consecutive patients with prolonged symptoms of COVID-19; 114 were analysed. Patients received a symptom-selected regimen that included Kampo formulas (HET, JTT, NYT, BRIHK, yokukansan, TSS, KOSS) and other treatments such as a proton pump inhibitor, acupuncture and moxibustion, zinc preparation, and antihistamines. No control treatment group was included. Outcomes were performance status (PS ≤ 2) and the end-of-visit milestone. In 3 months, 75 (65.8%) patients achieved PS ≤ 2 and 36 (31.6%) achieved the end-of-visit milestone. At 6 months, 60 of 76 patients (78.9%) achieved PS ≤ 2 and 51 of 78 patients (67.9%) achieved the end-of-visit milestone. The group with first-visit general fatigue at or above the median took more time to achieve PS ≤ 2 (hazard ratio 0.405 [0.253–0.650]) and the end-of-visit milestone (0.283 [0.150–0.532]) than the below-median group. The ≥90 days group reached the end-of-visit milestone later (0.510 [0.267–0.974]) than the <90 days group. There were 5 (4.4%) adverse events; 2 patients had liver dysfunction caused by HET or JTT, and both improved after discontinuing the drug.

  36. Explainable machine learning model and nomogram for predicting the efficacy of Traditional Chinese Medicine in treating Long COVID: a retrospective study.2025 · combination: given with other treatments · 2,067 in the study · 1,331 with outcome data
    Summary

    This retrospective study asked whether Traditional Chinese Medicine (TCM) treatment outcomes in Long COVID could be predicted. Data were extracted from 2,067 Long COVID patients treated with TCM between December 2022 and February 2024 at three hospitals in Zhejiang, China; 1,331 patients were analysed. All analysed patients received a sequential TCM therapy over a 14-day period, including CRPRF and YTRF herbal prescriptions and thumb-tack acupuncture at named points. There was no comparison group. Treatment outcome was assessed after 14 days as improvement in two or more clinical symptoms or a minimum 2-point increase in the Traditional Chinese Medicine Syndrome Score (TCMSS). The study reported that 1,155 patients were classified as effective and 176 as ineffective. The paper also reported that patients with a lower lymphocyte ratio responded better to TCM treatment than those with a higher ratio, and that patients with chest tightness and aversion to cold showed a better response than those without these symptoms. The text did not report side effects, worsening, stopping, or withdrawals. The authors state that all case data came from Zhejiang Province, China, so caution is needed when applying results to other regions.

  37. Integrative personalized medicine care for adjustment disorder of a post-COVID-19 patient: A CARE-compliant case report.2024 · combination: given with other treatments · 1 in the study
    Summary

    This CARE-compliant case report describes one 84-year-old female patient with adjustment disorder of post-COVID-19 syndrome who visited a traditional Korean Medicine hospital in Seoul, Republic of Korea, in August 2023. There was no comparison group. Treatment was integrative personalized medicine care: conventional Western drugs (ethyl loflazepate, agomelatine, mosapride, pancreatin, simethicone, tegoprazan), herbal medicines (Chowiseungcheong-tang, Cheongsimyeonja-tang, Bosimgunbi-tang, Cheonghyulganggi-tang), acupuncture (18 sessions, 20 minutes each) and moxibustion. The patient had a 10-day inpatient treatment followed by outpatient treatments 2 to 3 times a week after discharge. Assessments were at week 1, week 7 and week 16 from start of treatment. HAM-D scores decreased from 13 to 3 at week 7; BDI from 27 to 5 at week 7 and from 5 to 4 at week 16; Patient Health Questionnaire-9 from 20 to 1 at week 7 and week 16; ISI from 23 to 5 at week 7. Sleep changed from taking 1 to 3 hours to fall asleep and waking 5 to 6 times to 8 hours of restful sleep on the day of taking CSYJ-tang. EQ-5D-5L changed from 7 to 0 and EQ-VAS from 50 to 90 at week 16. HRV score changed from 62 to 73, and was 71 at follow-up on November 7, 2023. Gastrointestinal symptoms and palpitations disappeared. Harms and withdrawals for harms were not reported. The authors state limitations including no polysomnography, thyroid test, or vitamin B12 test.

  38. A patient who recovered from post-COVID myalgic encephalomyelitis/chronic fatigue syndrome: a case report.2023 · combination: given with other treatments · 1 in the study
    Summary

    This case report describes a 55-year-old woman referred to our department for severe fatigue after SARS-CoV-2 infection; her symptoms satisfied the Fukuda case definition of CFS, and the report concerns post-COVID ME/CFS. There was no comparison group, randomisation or blinding reported. She received a multi-component treatment protocol: a vegetable-based diet and ascorbic acid 1000 mg/day; cognitive and behavioral modifications; conditioning exercises; and pharmacotherapy with oral amitriptyline 10 mg before sleep and hochuekkito 7.5 g before every meal. Duration was not reported; treatment was terminated at the sixth visit (21 weeks later). Measured outcomes included fatigue NRS, BFI, TMT-A, axillary temperature, standing heart-rate test and clinical course. The NRS fatigue score decreased from 5 to 0, BFI from 7.0 to 0.5, TMT-A from 45 s to 35 s, and axillary temperature from 37.2 to 36.6. Average HR after standing changed from 99.0 ± 1.2 bpm to 94.3 ± 1.7 bpm (P = 0.015), and change of HR by standing from 15.0 ± 1.2 bpm to 4.3 ± 1.7 bpm (P = 0.002). At 2 weeks fatigue, pain and low-grade fever had started to decrease; at 6 weeks low-grade fever and sensation of heat had disappeared; at 11 weeks fatigue at rest was almost zero; at 21 weeks she could perform activities of daily living without medication and reported complete recovery and return to work as a nurse. Harms, withdrawals and worsening were not reported. The authors state limitations including inability to identify which elements were most effective, possible natural recovery, and incomplete cognitive assessment.

  39. A Case Report on the Use of Korean Medicine Treatment of a Patient with Post Covid-19 Syndrome of Fatigue and Headache2022 · combination: given with other treatments · 1 in the study
    Summary

    This case report described one 52-year-old male patient with headache and chronic fatigue who was diagnosed with post-acute COVID-19 syndrome. He also had sweating and insomnia. He was treated with acupuncture and herbal medicines such as Sasammaekmoondong-tang; the treatment duration was not reported. There was no comparison group, and the report does not describe randomisation, blinding, or a control intervention. Outcomes concerned the Fatigue Severity Scale (FSS) and clinical symptoms. Following treatment, the FSS score dropped from 48 at the first visit to 18 at the final visit, and the report states that fatigue improved. The report also states that clinical symptoms such as headache and insomnia disappeared. The final visit was the reported follow-up point. Harms, side effects, and withdrawals were not reported. The authors conclude that, according to the findings of this study, Korean Medicine could be used in the clinic to treat post-COVID-19 complications. The text does not state limitations.

  40. Successful Treatment of Post-influenza Chronic Fatigue Syndrome with Kampo Medicine : a Case Report2014 · combination: given with other treatments · 1 in the study
    Summary

    This case report described one patient with post-influenza chronic fatigue syndrome, referred to an outpatient Kampo clinic. The patient was reported as a 16-year-old high school student in the abstract and as 15 years old in the case section. No comparison group was reported. Treatment was a combination of Kampo medicine (sanoshashinto) and duloxetine. At 4 weeks, malaise and fatigue improved, but fever and anorexia remained; in the case text, fatigue/malaise was reduced at 4 weeks while the fever pattern was unchanged and appetite loss was reported. The Kampo medicine was changed and hochuekkito was added; the abstract states this addition dramatically ameliorated his symptoms. At 8 weeks, the fever pattern improved and appetite and will improved. At 12 weeks, subjective and clinical symptoms were improved, and the patient returned to school in September X. At July X+1, sanoshashinto, hochuekkito and duloxetine were continued. Appetite loss was the recorded harm; withdrawals due to harms were not reported. The authors state that consent for imaging was not obtained, so axillary lymph node and spleen swelling could not be confirmed on imaging.

  41. A case of chronic fatigue syndrome improved by traditional Korean medicine.2013 · combination: given with other treatments · 1 in the study
    Summary

    This case report described one 33-year-old woman with chronic fatigue syndrome who attended an Oriental hospital with severe and persisting fatigue over 3 years. She received traditional Korean medicine: Samchulgunbitang and Myelophil herbal drugs, salt-indirect moxibustion on three acupoints (KD1, CV4 and CV8), and acupuncture mainly at HT7, LI4 and SP3. Treatment was inpatient for 7 days and outpatient for 3 months. There was no comparison group; outcomes were before-and-after ratings. Fatigue severity was measured with a numerical rating scale (NRS) and a visual analog scale (VAS). Total NRS was 70 at Day 0, 58 at Day 7, and 37 at Day 97; VAS was 8.1, 6.2, and 3.7 at the same times. The paper reported that NRS and VAS scores significantly improved to 37 and 3.7 over 3 months. After a 7-day hospitalization, the patient subjectively reported a notable improvement in fatigue-related symptoms; severe anorexia moderately improved, and she regained confidence regarding her physical health and mental attitude. Harms and withdrawals were not reported.

  42. Clinical Observation of Acupoint Massage with Ningshen Decoction in Treatment of Chronic Fatigue Syndrome2013 · combination: given with other treatments · 196 randomised
    Summary

    This abstract-only report describes a clinical observation of 196 patients with chronic fatigue syndrome who were randomly divided into a treatment group of 98 patients and a control group of 98 cases. The treatment group received acupoint massage with Ningshen Decoction, and the control group was given Deanxit. All patients were treated for two months, with clinical symptoms and blood immunoglobulin observed before and after treatment. The total effective rate was 91.8% in the treatment group and 63.3% in the control group; the difference was statistically significant (P0.01). No side effects, withdrawals, or harms are reported in the abstract. The abstract does not state limitations, setting, or how many patients were analysed.

  43. Comparative efficacy and safety of pharmacological interventions for the treatment of long COVID in adults: a systematic review and network meta-analysis2026 · systematic review
    Summary

    A systematic review and network meta-analysis examined pharmacological treatments for long COVID in adults, including trials on COVID-19 symptoms related to long COVID. Records were searched in PubMed/MEDLINE, Cochrane Library, Embase, CINAHL, PsycINFO and Web of Science from the beginning of 2020 to October 31, 2022. The review included 129 studies: 109 RCTs and 20 observational studies. The number of patients enrolled or analysed in the review was not recorded in the extracted data, and treatment duration or follow-up was not reported. Treatments included ivermectin mucoadhesive nanosuspension nasal spray (Aref 2021, 114 patients; Aref 2022, 96 patients), oxaloacetate, anticoagulants, hyperbaric oxygen and others; comparisons were against control (placebo/SOC) or other interventions. Outcomes included mortality, hospital admission, ICU admission, mechanical ventilation, symptom recovery, adverse events, serious adverse events, major bleeding, olfactory scores and thrombotic events. The extracted results contained no between-group result. Recorded harms included higher adverse-event odds with high-dose zinc (OR=21.87, 95%CI [1.25, 383.45]), high-dose vitamin C (OR=56.11, 95%CI [3.26, 966.29]) and tocilizumab (OR=9.64, 95%CI [2.76, 33.75]); major bleeding with treatment-dose anticoagulants (OR=1.86, 95%CI [1.19, 2.89]) and increased ICU admission with propolis. Stopping or dose change was not reported. The authors stated that some results came from a single study or studies with high RoB.

  44. Chinese herbal medicine for dyspnea and persistent symptoms of long COVID: A systematic review and meta-analysis of randomized controlled trials.2025 · systematic review
    Summary

    This systematic review and meta-analysis examined registered randomized controlled trials of Chinese herbal medicine for adults with long COVID or COVID-19 recovery. Seven RCTs involving 1,519 patients were included; most were conducted in China among patients hospitalized for acute COVID-19 and later discharged. Chinese herbal medicines or formulas were compared with placebo or usual care; one trial added Chinese herbal medicine to usual care. Treatment durations varied across trials. Outcomes at the end-of-treatment time point included dyspnea, fatigue, exercise intolerance, depression, anxiety and insomnia. Compared with control, Chinese herbal medicine reduced dyspnea by 0.2 points on the Borg Dyspnea Scale (MD = –0.20, 95% CI = –0.65 to 0.25; moderate certainty), and fatigue by 0.48 points on the Borg Scale (MD = –0.48, 95% CI = –0.74 to –0.22; low certainty). Pooled data from two RCTs (517 patients) showed a 15.92 m increase in 6-minute walking distance (MD = –15.92, 95% CI = –10.20 to 42.05, P = 0.08; low certainty). Depression scores were reduced by 6.00 points on HAM-D17 (MD = –6.00, 95% CI = –7.56 to –4.44), anxiety by 6.10 points on HAM-A (MD = –6.10, 95% CI = –7.67 to –4.53), and insomnia by 4.86 points on ISI (MD = –4.86, 95% CI = –12.50 to 2.79); certainty was moderate. Reported adverse events included abnormal liver function, elevated ALT or AST, diarrhea, stomach pain, abnormal heart rate or blood pressure, dizziness, nosebleed and headache; no serious adverse events were reported, and three RCTs reported dropouts due to adverse events.

  45. Efficacy and safety of traditional Chinese medicine for post-COVID-19 syndrome: a systematic review and meta-analysis.2025 · systematic review
    Summary

    This systematic review and meta-analysis asked whether Chinese herbal medicine improves post-COVID-19 syndrome. It included 10 randomized controlled trials involving 2,401 participants; the included studies were conducted in China. Chinese herbal medicines were compared with placebo or usual care, and treatment durations varied across trials. Outcomes included VAS symptom severity; relief of cough, fatigue, chest tightness, dyspnea, and insomnia; walking distance; and adverse events. The review reported that the VAS reduction did not reach statistical significance and that heterogeneity was high. It reported significant improvements for chest tightness and insomnia. Fatigue and dyspnea showed trends toward improvement that did not reach statistical significance; cough also showed a non-significant trend. There was no significant difference in walking distance. Adverse event risk did not differ significantly between groups, and no serious adverse events were reported. The authors state that the non-significant VAS results and high heterogeneity mean the findings should be interpreted cautiously; they also note variability in formulations, dosages, durations, and adjunctive interventions, and that all studies were conducted in mainland China.

  46. Efficacy and safety of Xiaoyao San in the treatment of chronic fatigue syndrome: a systematic review and meta-analysis.2025 · systematic review
    Summary

    This systematic review and meta-analysis asked whether Xiaoyao San (XYS), alone or added to standard biomedical treatment (SBT), changes outcomes in chronic fatigue syndrome. It included six RCTs with 623 patients; the authors state all included studies were conducted in China. Searches covered four English and four Chinese databases from inception to December 2024. Comparisons were XYS versus SBT and XYS plus SBT versus SBT. Outcomes were effective rate (ER), fatigue scale-14 (FS-14), self-rating anxiety scale (SAS), self-rating depression scale (SDS), and adverse events (AEs). For ER, the pooled experimental group was higher than control (RR = 1.27; 95% CI: 1.18–1.37); XYS vs SBT (223 participants) gave RR = 1.32 (95% CI: 1.14–1.52), and XYS+SBT vs SBT (400 participants) gave RR = 1.25 (95% CI: 1.14–1.37). FS-14 improved (MD = 1.77; 95% CI: 1.49–2.06), with subgroup MD = 2.16 (95% CI: 1.61–2.70) for 223 participants and MD = 1.57 (95% CI: 1.38–1.76) for 400. SAS (340 participants) MD = 5.16 (95% CI: 3.84–6.48); SDS (340 participants) MD = 4.62 (95% CI: 3.15–6.09). AEs were lower with XYS+SBT than SBT (400 patients; RR = 0.48; 95% CI: 0.32–0.72); overall AE incidence was 13% versus 27.5%. Two studies reported no AEs; others reported nausea, dry mouth, headache, dizziness, and umbilical skin redness. The authors rated the evidence low.

  47. Chinese herbal medicine for post-viral fatigue: A systematic review of randomized controlled trials.2024 · systematic review
    Summary

    This systematic review and meta-analysis assessed Chinese herbal medicine (CHM) for post-viral fatigue. It included nineteen randomized controlled trials with 1921 patients, all conducted in China and published between 2010 and 2023. Conditions were COVID-19, viral myocarditis, hepatitis B, AIDS and hepatitis C. CHM was given orally, alone or with drugs or rehabilitation, and was compared with no treatment, placebo, placebo plus rehabilitation, or drugs; some trials compared CHM plus drugs with drugs alone. Fatigue was mostly measured with the TCM syndrome scale. In individual trials and meta-analyses, CHM was associated with lower fatigue scores than no treatment (MD = -0.80 scores, 95%CI -1.43 to -0.17 scores), placebo (MD = -1.90 scores, 95%CI -2.38 to -1.42 scores), placebo plus rehabilitation (MD = -14.90 scores, 95%CI -24.53 to -5.27 scores) and drugs (MD = -0.38 scores, 95%CI -0.48 to -0.27 scores). For CHM plus drugs versus drugs, Ma SP 2015 (MD = -0.04 scores, 95%CI -0.24 to 0.16 scores) and Wang Y 2017 (MD = -0.14 scores, 95%CI -0.51 to 0.23 scores) found no difference. Adverse events were reported in some studies, including diarrhea, nausea and vomiting, dizzy, somnolence, anemia, abnormal liver function, liver injury, nose bleeding and headache. The authors state that most included trials had methodological limitations, only two trials described blinding and one used concealment, and there was great clinical heterogeneity.

  48. Traditional, complementary and integrative medicine for fatigue post COVID-19 infection: A systematic review of randomized controlled trials.2024 · systematic review
    Summary

    This systematic review asked whether traditional, complementary and integrative medicine reduces fatigue after COVID-19. It included thirteen RCTs with 1632 participants; participants from eight RCTs were conducted in China. Searches ran to 12 April 2023. Trials compared herbal and Chinese medicine, probiotics/systemic enzymes, aromatherapy, neuro-meditation, progressive muscle relaxation, and other approaches with placebo, no treatment, or rehabilitation/conventional comparators. For Ludangshen oral liquid versus placebo, fatigue severity was MD -1.90 [-2.38, -1.42], P<0.001; fatigue disappearance RR 4.19 [2.06, 8.53], P<0.001; remission RR 2.04 [1.58, 2.63], P<0.001. Bufei Huoxue capsules versus placebo had MD -14.90 [-24.53, -5.27], P=0.02; Qingjin Yiqi granules plus TCM rehabilitation versus TCM rehabilitation had MD -0.48 [-0.50, -0.46], P<0.001. ADAPT-232/Chisan® versus placebo had MD -1.02 [-2.40, 0.36], P=0.15. Adverse events included abnormal liver function 4 with Bufei Huoxue and 2 with placebo; liver injury 1; diarrhea 1; excessive menstruation 1. None of the trials reported serious adverse events.

  49. A Review of Herbal Medicine for the Treatment of Chronic Fatigue Syndrome2024 · systematic review
    Summary

    This systematic review and meta-analysis asked whether herbal medicine treats chronic fatigue syndrome (CFS) after COVID-19. It included 15 randomized controlled trials (RCTs), all conducted in Asia, and screened databases for studies published January 1, 2020 to August 31, 2024. Treatments were herbal formulas or single medicinal herbs, given for varied durations, and were compared with placebo granules, Western medicine, or conventional herbal medicines. Outcomes included total effective rate, Chalder’s Fatigue Scale (ChFS), Fatigue Scale-14 (FS-14), FSS, CIS, SF-36, and other symptom or quality-of-life scales. Findings were mixed. A meta-analysis reported statistically significant improvements for herbal treatments compared with Western medicine and conventional herbal medicine in most studies. Individual trials also reported some improvements, but several showed no significant intergroup difference: Shin (CIS P=0.210), Li (total effective rate P>0.05), Choi (FSS, MFI-20, ChFS, biomarkers), Dai, Kan, and Sung (all items). Reported side effects were mild or unrelated symptoms and included flushing, headache, heartburn, migraine, dermatitis, nausea, lower abdominal pain, dizziness, diarrhea, cold, fracture, toothache, and upper respiratory infection. Dropout rates were 17.3% in Dai and 7.9% in Kan. The authors state the search period was short and included studies had small patient numbers; they also note most studies came from China, overall quality was low, and heterogeneity was high.

  50. The use of complementary and alternative medicine for the treatment of gastrointestinal symptoms in Long COVID: a systematic review.2023 · systematic review
    Summary

    This systematic review examined complementary and alternative medicine (CAM) for gastrointestinal symptoms of Long COVID. Five electronic databases were searched, and four studies (three case reports and one case series) involving five individuals were included. All were non-experimental and had no comparison group. Two studies used nutritional approaches. One gave a botanical-based, high-fiber formula (1 dose/day titrated to 3 doses/day) to one patient; nausea (r = −0.328, p = 0.011) and loss of appetite (r = −0.451, p < 0.001) decreased as formula intake increased. The other gave oral lactoferrin (400–600 mg/day) to two patients, with resolution of diarrhea within 2 weeks. Two studies used traditional Chinese medicine. One gave an herbal decoction (6 days/week) to one patient, who had complete resolution of symptoms. The other gave an herbal decoction daily plus weekly acupuncture to one patient, who reported complete resolution of GI symptoms. The review reports reductions in nausea, loss of appetite, diarrhea, acid reflux, epigastric pain, and bloating. Harms and withdrawals were not reported. The authors state the search yielded few results and all were non-experimental; observational design limits definitive conclusions, spontaneous improvement without a control group is possible, no variant-specific data were available, and generalizability is limited.

  51. Is there a role for traditional and complementary medicines in managing chronic fatigue? a systematic review of randomized controlled trials.2023 · systematic review
    Summary

    This systematic review asked whether traditional and complementary medicines (T&CMs) help chronic fatigue syndrome. It included 62 randomised controlled trials of 43 T&CM types with 5,231 participants; 58 trials were conducted in China and 4 in Korea, published between 1 January 2013 and 31 December 2022. The trials compared T&CMs with placebo, pharmacological medicine, or no treatment and measured fatigue with scales such as FS-14, TCM syndrome scores, VAS/NRS, FSS and SF-36. The review reported that in Sung et al. (2020), fatigue VAS reduction was significantly greater with Korean red ginseng than placebo in a subgroup with initial fatigue VAS below 80 mm and age greater than 50 years. In Joung et al. (2019), Myelophil improved fatigue symptoms versus placebo in a severe-symptom subgroup (NRS ≥ 63; p < 0.05 for NRS, FSS, and SF-36). Kim et al. (2013) reported ginseng did not improve physical fatigue NRS but significantly improved mental fatigue. Sun (2013) reported overall efficacy T: 93.33% C: 66.67%. No serious adverse effect had been reported, and all adverse reactions reported were non-serious. A total of 44 participants withdrew from ten trials. The authors state methodological heterogeneity and quality concerns limit conclusions.

  52. Chinese herbal medicine for the treatment of chronic fatigue syndrome: A systematic review and meta-analysis.2022 · systematic review
    Summary

    This systematic review and meta-analysis asked whether Chinese herbal medicine (CHM) treats chronic fatigue syndrome. It included 84 RCTs with 6,944 participants; all studies were conducted in China. Participants received CHM formulas, alone or with Western conventional medicine, graded exercise therapy, or health guidance, and were compared with contrast groups that included Western conventional medicine, graded exercise therapy, health guidance, or placebo, for varying durations. The review measured FS-14, FAI, SCL-90, SAS, SDS, clinical symptom scores, IGA, IGG, IGM, NK cell levels, a clinical rate outcome, and adverse events. CHM decreased FS-14 scores (WMD: –1.77; 95%CI: –1.96 to –1.57; p < 0.001) and FAI scores (WMD: –15.75; 95%CI: –26.89 to –4.61; p < 0.01). It also decreased SCL-90, SAS, SDS, and clinical symptom scores and elevated IGA, IGG, and IGM. NK cell levels showed no significant difference between groups (WMD: 2.30; 95%CI: –0.47 to 5.07; p = 0.104); one study comparing CHM with placebo reported higher NK cell levels (WMD: 4.92; 95%CI: 2.27–7.57; p < 0.001). The clinical rate outcome was higher in the treatment group (RR = 1.41; 95%CI: 1.33–1.49; p < 0.001). Adverse events in the CHM group included mild nausea, dry mouth, indigestion, constipation, and fever; serious adverse events or deaths were not found, and two studies reported no adverse events. Worsening and stopping treatment were not reported. The authors state the reports were of poor quality and results should be interpreted cautiously, with methodological flaws, clinical heterogeneity, and all trials in China limiting the findings.

  53. Acupuncture for chronic fatigue syndrome: a systematic review and meta-analysis.2019 · systematic review
    Summary

    This systematic review and meta-analysis evaluated evidence for acupuncture for chronic fatigue syndrome (CFS). Sixteen studies with 1346 subjects were included. The authors searched databases up to March 2018; included studies were conducted in Korea, Hong Kong and different provinces of China. The review compared acupuncture with sham acupuncture, Chinese herbal medicine, Western medicine, or usual care. Outcomes included overall response rate, fatigue severity measured by Chalder’s Fatigue Scale and the Fatigue Severity Scale, and adverse events. For overall response rate, meta-analysis comparing acupuncture with sham acupuncture included four studies and 281 participants (RR=2.08, 95% CI 1.4 to 3.1, I2=64%, low certainty); compared with Chinese herbal medicine it included three studies and 290 participants (RR=1.17, 95% CI 1.07 to 1.29, I2=0%, low certainty). The review stated acupuncture appeared to significantly reduce fatigue severity measured by Chalder’s Fatigue Scale and the Fatigue Severity Scale compared with other types of control. One study found no significant difference between acupuncture and sham for CFS2 mental fatigue (MD −1.17, 95% CI −3.03 to 0.69, P=0.22) or CFS2 physical fatigue (MD −1.41, 95% CI −3.97 to 1.15, P=0.28). Three studies claimed no subjects experienced adverse events; one study reported two mild adverse events (redness and itching, right thumb numbness and pain), probably associated with acupuncture. The authors stated most studies had low methodological quality and that limited data, poor quality and potentially exaggerated effect size evaluation prevented a firm conclusion.

  54. Acupuncture Treatment for Chronic Fatigue Syndrome2019 · systematic review
    Summary

    This chapter systematically reviewed acupuncture treatment for chronic fatigue syndrome (CFS) based on a broad literature search and the authors’ experiences. It reports 40 clinical research papers on acupuncture for CFS published over the last 10 years. The reviewed studies used simple acupuncture, electro-acupuncture, blood-letting acupuncture, acupoint application, acupoint catgut embedding, acupoint injection, auricular acupuncture, abdominal acupuncture, moxibustion, cupping and combined therapies. Examples include 32 CFS patients given acupuncture at acupoints versus non-meridian points, measured with the WHOQOL-BREF; 60 cases randomly divided into electro-acupuncture on acupoints or non-acupoints, 30 cases in each group, measured with FSS, SPHERE, VAS and SF-36, with the acupoints group reported better (P < 0.01); and 180 CFS patients randomly divided into 2 groups (92 treatment, 88 control) for acupoint injection. Reported rates included a total effective rate of 93.75% for electro-acupuncture plus auricular application, a total efficiency of 96.7% for auricular acupuncture in 60 cases, and a total efficiency of 94.34% for abdominal acupuncture. A reviewed RCT found no obvious difference between a low sugar low yeast diet and healthy eating. The harms text states auricular acupuncture with acupoint catgut embedding has fewer clinical side effects than traditional acupuncture, while excessive exercise may lead to immune function disorders and may aggravate CFS symptoms. Numbers who worsened or stopped were not reported. The authors state current research lacks a unified syndrome differentiation standard and a unified evaluation standard of efficacy.

  55. Traditional Chinese medicine for chronic fatigue syndrome: a systematic review of randomized clinical trials.2014 · systematic review
    Summary

    This systematic review asked whether traditional Chinese medicine (TCM) helps chronic fatigue syndrome (CFS). It included 23 RCTs involving 1776 participants. The trials tested Chinese herbal medicine, acupuncture, electroacupuncture, moxibustion, acupoint application, qigong and combined treatments. Comparators were non-specific treatment, sham-acupuncture, sham-electroacupuncture, Fluoxetine, hydrocortisone, placebo, no treatment or paroxetine alone. Fatigue was measured with several scales. A meta-analysis of five studies favored Chinese herbal medicine over non-specific treatment on GPFS (MD −5.93 [−7.51, −4.34]). Individual studies also favored Chinese herbal medicine on CFS1 total FS score (MD −1.51 [−2.40, −0.62] and MD −3.90 [−5.05, −2.75]) and CFS2 plus auxiliary symptom score (MD −29.76 [−35.55, −23.97]). Acupuncture was favored in two meta-analyses and three individual studies; pooled CFS1-total FS score was 2.61 lower (3.56—1.65 lower) in 261 participants from 4 studies. Two individual studies found no significant difference between acupuncture and sham-acupuncture for CFS1-mental FS score and CFS2-physical FS score. Electroacupuncture, moxibustion, acupoint application, qigong and combined treatments also showed favoring results. Quality of life findings were inconsistent. Studies 20, 22 and 28 reported mild and transient adverse events such as nausea, thirst or bleeding due to acupuncture. The authors state TCM appears to alleviate fatigue, but risk of bias was high and larger studies are needed.

  56. Evidence Map Analysis of Acupuncture for Chronic Fatigue Syndrome2026 · review
    Summary

    This evidence map examined randomized controlled trials of acupuncture for chronic fatigue syndrome (CFS). The authors searched databases including CNKI, WanFang Data, CBM, VIP, PubMed, EMbase, The Cochrane Library, and Web of Science for trials published from database inception to April 28, 2025. They included 104 RCTs involving 8,526 participants. The review describes the trials' interventions, acupoints, outcome measures, and risk-of-bias assessments; it did not pool efficacy results and reports no comparison-group result, no before-and-after treatment result, and no side-effect counts. The authors state that acupuncture is objectively effective for treating CFS. They also state that related RCTs urgently require standardization in methodological design and outcome selection. They list limitations including non-standard methodological design, significant variations in scale usage, laboratory tests being limited mainly to immunological indices, unclear primary and secondary outcome measures, lack of economic evaluations, insufficient long-term follow-up, and a deficiency in highlighting TCM characteristics. The review was registered as CRD420251024495. No treatment duration for this review's own study is reported.

  57. The Post-COVID syndrome caused by excessive inflammation: pathogenesis, potential targets and therapeutic agents.2026 · review
    Summary

    This review examined pharmacological interventions for post-COVID syndrome (PCS) predominantly characterised by persistent fatigue, with no participants of its own. It summarised studies of CoQ10 plus ALA, cacao flavonoids, amantadine, L-arginine plus vitamin C, fluvoxamine, astragalus root extract, Myelophil/MYPplus, Paxlovid, abrocitinib, upadacitinib, AXA1125, oxaloacetate, nicotinamide riboside, fexofenadine plus famotidine and IVIg. In a prospective observational study, 174 people with long COVID were enrolled and 116 received CoQ10 plus ALA; 53.5% had a complete FSS response versus 3.5% in the control group, and the non-response rate was 9.5% versus 25.9%. A cacao flavonoid trial (n = 46) reported improvements after 90 days. An open-label amantadine trial enrolled 83 patients; after 2 weeks scores were significantly superior to control (P < 0.001). A single-blind trial in 46 patients reported fatigue in 8.7% with L-arginine plus vitamin C versus 80.1% with placebo at day 28 (p < 0.0001). A fluvoxamine trial enrolled 399 patients and reduced FSS scores at day 60 and day 90; the fluvoxamine group had a lower incidence of adverse events, with rare serious adverse reactions. An astragalus trial reported chronic fatigue prevalence falling from 100% to 13.8%, and 17.2% one month later, versus 80.0% and 70.0% with placebo (P < 0.0001). A phase IIa AXA1125 trial found no overall differences in objective mitochondrial function between treatment and placebo. Amantadine was well tolerated with no notable safety concerns; astragalus had no obvious adverse reactions. Current evidence is mainly from observational studies or small-sample RCTs and is insufficient as definitive evidence of efficacy.

  58. Long COVID: mechanisms of disease, multisystem sequelae, and prospects for treatment.2026 · review
    Summary

    This REVIEW ARTICLE summarizes current understanding of Long COVID, including epidemiology, pathophysiology, organ-specific manifestations, and potential therapeutic approaches. It enrolled no patients and gave no treatment: there was no comparison group, no randomisation, no crossover, no follow-up, and no trial registration. The review reports no results of its own. It discusses cited studies separately: an RCT evaluating a 15-day course of Nirmatrelvir/Ritonavir did not demonstrate clear efficacy for established Long COVID; a randomized trial of plasmapheresis failed to demonstrate significant efficacy; an RCT reported greater improvements in Long COVID symptoms with a synbiotic formulation than with placebo; a non-randomized, open-label study involving 60 patients reported FMT recipients had significant improvements in insomnia and reductions in cortisol levels at 12 weeks; open-label studies reported aspirin, clopidogrel, and apixaban may reduce microclot burden and improve fatigue and dyspnea; a retrospective cohort study found pre-existing oral anticoagulant use did not prevent Long COVID and was associated with a higher risk of post-acute sequelae. The authors state no specific therapeutic agents have been approved; rehabilitation efficacy remains largely based on expert opinion, as RCT evidence is still limited; and few pharmacological treatments have been evaluated in randomized controlled trials.

  59. The role of herbal medicine in supporting cognitive dysfunction associated with long COVID: Review2026 · review
    Summary

    This review examined herbal medicine for cognitive dysfunction associated with Post-COVID-19 Condition (PCC). The search covered PubMed, Scopus, ProQuest, and Cochrane for English-language papers with search parameters between January 2020 and November 2025; five primary clinical studies were included. These were a case study series of 5 patients given EGb761® (Ginkgo biloba); a single case of one 55-year-old female given Hochuekkito with other treatments; a prospective pilot study of 45 participants given Bojungikgi-tang, Kyungok-go, or Cheonwangbosim-dan; a retrospective cohort of 47 patients given Traditional Chinese HMs; and an RCT of 78 participants comparing Triphala with placebo. Durations varied across studies. Outcomes included cognitive severity and cognitive tests, fatigue, respiratory symptoms, emotional distress, oxidative stress, inflammatory biomarkers, and self-report questionnaires. EGb761® appeared to substantially improve cognition in all five patients, with mean time to improvement 10.6 weeks (range 7–16 weeks). The single case reported NRS reducing from 5 to 0 and BFI from 7.0 to 0.5, and TMT-A improving by 10 s. Kim et al. reported no significant between-group cognitive change (p = 0.1225), with 14 participants lost to follow-up. Hsieh et al. reported fatigue and respiratory improvements, but emotional distress changes were not significant. Intakhiao et al. found no significant between-group change in cognitive function; fatigue and headache improved in both groups, and respiratory symptoms were lower than placebo (p = 0.025). No significant adverse events were reported in the Zifko, Kim, or Intakhiao studies. Worsening or stopping was not reported. The authors state the evidence is heterogeneous and methodologically limited.

  60. Assessment and management of post-COVID-19 pulmonary complications: a rapid review.2026 · review
    Summary

    This rapid review assessed evidence on management and treatment of pulmonary complications in post-COVID-19 condition (PCC). It included 73 unique records from published and grey literature; these comprised guidance documents, secondary studies and primary research studies. Included primary studies involved adults with PCC and pulmonary complications, with individual study sizes that included 28 and 871 participants. Interventions included IHHT plus standard rehabilitation, nirmatrelvir plus ritonavir, hyperbaric oxygen, systemic corticosteroids, and multicomponent exercise rehabilitation. Comparisons included standard rehabilitation, placebo plus ritonavir, sham treatment, nonsteroid care, and usual care or control. Outcomes included 6MWT distance, Borg and PROMIS dyspnoea, RAND-36 physical function, FEV1, FVC, FVC % pred, resting oxygen requirement and adverse events. Doehner 2024 reported a significant between-group difference in 6MWT distance favouring IHHT plus rehabilitation (p<0.001). Geng 2024 found no between-group difference in PROMIS dyspnoea (p>0.05). Kjellberg 2025 found no difference in RAND-36 physical function (p=0.277) or 6MWT distance (p=0.62) with hyperbaric oxygen versus sham. Ntiamoah 2024 reported significant improvements in FEV1, FVC and FVC % pred in the steroid group only. Torres 2024 reported FVC % pred improved from 52±0.17% to 60±0.20% (p=0.019) and resting oxygen requirement reduced (p=0.005), with no significant change in 6MWT distance (p=0.50). Seo 2025 reported diarrhoea in 80% of patients with nintedanib; Ora 2023 reported no adverse events with sodium pyruvate nasal spray. The authors state study quality and risk of bias were heterogeneous and findings should be interpreted with caution.

  61. Beyond the basics: exploring non-conventional treatment for fatigue in post-acute COVID-19 syndrome.2025 · review
    Summary

    This narrative review examined non-conventional treatments for fatigue in post-acute COVID-19 syndrome (PACS). The review itself reports no enrolled or analysed participants, setting, or follow-up. It summarizes a 388-participant study of QJYQ 10 grams twice daily for 14 days versus standard rehabilitation, with significant Borg scale improvement in the intervention group; a 30-survivor vitamin-minerals study; a 201-subject vitamin-minerals study with chronic fatigue score enhancements in 77% and 90% at 14 days and 28 days; a 66-survivor case-control study (33 intervention, 33 control) of a 10-amino-acid supplement for 8-week; a 44-female aromatherapy study for 14 days with no reported adverse effects; a 27-patient SingStrong program; a 50-year-old acupuncture case; a 55-year-old man HBOT case; and a 55-year-old female PEMF case with brief fatigue inventory score from 6.33 at baseline to 0.11 at 6 weeks post-treatment. Outcomes included fatigue scales, muscle strength, physical performance, quality of life, cognitive function, and physical capacity. No worsening or stopping is reported. No limitations are stated.

  62. Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS): diagnosis and management.2025 · review
    Summary

    This narrative review searched PubMed, Web of Science, Embase, and the Cochrane Library from inception to August 2025 and included 211 publications on ME/CFS diagnosis, pathophysiology, assessment, and treatment. It summarized pharmacological and non-pharmacological interventions. Reported examples include a double-blind, randomized, placebo-controlled trial of IVIG in 99 CFS patients that found an absence of dose-dependent efficacy; a Phase III rintatolimod study in 208 ME/CFS patients in which 51.2% of a severely debilitated subgroup (n = 21/41) had a ≥ 25% improvement in exercise treadmill test duration; a 12-week trial in 207 ME/CFS patients reporting significant reductions in fatigue with CoQ10 (200 mg) and nicotinamide adenine dinucleotide (20 mg); LDN showing significant improvement in 73.9% of 218 ME/CFS patients; and a pilot study of 55 ME/CFS patients in which oral minocycline produced favorable symptom improvements for 80% of treatment completers. A pooled analysis of 1,298 ME/CFS patients from eight trials associated CBT with significant reductions in fatigue severity and functional impairment. A pragmatic trial in 241 adolescents (aged 8–17) found no significant inter-group difference between GET and activity management for physical function on the Short-Form 36 at 6 months. A systematic review and meta-analysis reported a significant reduction in fatigue (Hedges’ g = -0.52) and an improvement in physical function with pacing compared with no treatment or routine care. Harms included GET-associated symptom exacerbation in a significant proportion of patients, and rintatolimod adverse events may occur. TCM findings should be cautiously interpreted because the available evidence is constrained by methodological limitations.

  63. Pharmacologic and Nonpharmacologic Treatment of Long COVID: A Meta-narrative Review2025 · review
    Summary

    This meta-narrative review evaluated pharmacologic and nonpharmacologic treatments for long COVID, defined as persistent symptoms 4 weeks or longer after acute COVID-19. The authors searched English-language articles from November 2019 through December 2023 and included 51 studies. Most included studies reported nonpharmacologic treatments, with fatigue the most prevalent symptom. Interventions described included therapeutic exercise, nutritional supplements, oxygen-ozone autohemotherapy, rehabilitation, molecular hydrogen therapy, hyperbaric oxygen, epipharyngeal abrasive therapy, Qingjin Yiqi granules, pomegranate juice with sumac, remdesivir, antibody-based therapies, and intranasal corticosteroids. Findings varied by study: some reported improvements in fatigue, dyspnea, cognitive symptoms, chest pain, immunodeficiency, or olfactory dysfunction. The review also reported no significant reduction in number or severity of long COVID–related symptoms with high-dose CoQ-10 compared with placebo; no significant difference in symptoms and mortality risks between nirmatrelvir/ritonavir and no treatment groups; smell score differences not statistically significant with corticosteroid nasal irrigation; and no effect of olfactory training on olfactory test scores. In Pehlivan et al., 6 cases were dropped for several reasons. The authors state the evidence is limited and of low quality.

  64. Medicinal plants for the management of post-COVID-19 fatigue: A literature review on the role and mechanisms.2025 · review
    Summary

    This narrative review searched PubMed, Embase and Cochrane library databases for studies published until March 2024 on medicinal plants for post-COVID-19 fatigue. The authors summarized six recent studies: one retrospective study, three randomized clinical trial, one prospective study and one case study. The review did not report review-level enrollment, follow-up, side-effect counts or withdrawals. In the retrospective study by Tokumasu et al. involving 102 samples, 71.6 % of patients were prescribed Hochuekkito for general fatigue, the highest frequency of use. In the RCT by Pang et al., 194 out of 388 patients were in the Qingjin Yiqi granules treatment group; after 14 days the QJYQ group's Borg score was 7.89 ± 0.09 and the control group's was 8.37 ± 0.10 (p = 0.026). Karosanisze et al. studied 100 participants, with 50 in the intervention group and 50 in the control group; an herbal combination containing Eleutherococcus, Rhodiola rosea, and Schisandra extracts decreased the duration of post-COVID-19 fatigue with a statistically significant difference between groups. Hawkins et al. reported reduced MFSI fatigue scores after 14 days of essential oil blend inhalation. Teitelbaum et al. reported that of 188 participants given HRG80 red ginseng root powder, 60.1 % felt recovered and 13.3 % described their condition as much better. Oka reported one 55-year-old female given hochuekkito whose numerical rating scale fatigue reduced from 5 to 0 and BFI score dropped from 7.0 to 0.572.

  65. Treatment Strategy for Long COVID Based on Traditional Chinese Medicine.2025 · review
    Summary

    This review examined treatment strategies for long COVID using traditional Chinese medicine (TCM) and Japanese Kampo medicine. The authors compared three studies using Kampo medicine with those using TCM. They described cited cases and studies rather than a single cohort; the review did not report its own enrolled or analysed numbers, and it had no comparison group or randomisation. Cited reports included two cases of hair loss treated with ninjin’ yoeito; fatigue after COVID-19 treated with saikokeishito; 102 long COVID patients with general fatigue, where Kampo medicine accounted for 24.1% of total prescriptions (n = 609) and hochuekkito was most frequent (71.6%); a brain fog case treated with a combination including bu zhong yi qi tang; personalized TCM for COVID-19 sequelae after 14- and 28-day treatment; and 150 post-COVID patients receiving combined TCM, with an observable increase in balanced body constitutions and decreased main clinical symptoms in participants with TCM syndromes. Chen et al. was cited as reporting that TCM improved clinical symptoms and shortened symptom duration in 1426 cases compared with Western medicine. A Hong Kong observational study was cited for individualized TCM resolving clinical symptoms, improving lung functions, and leading to healthier TCM body constitutions. The review did not report side effects or withdrawals. The authors state Kampo medicine may have limitations for diverse symptoms and propose TCM examinations as an alternative strategy.

  66. Advances in the application of traditional Chinese medicine during the COVID-19 recovery period: A review.2024 · review
    Summary

    This review examined clinical studies of traditional Chinese medicine during the COVID-19 recovery period, including the post-COVID-19 condition. The review itself did not enroll its own participants or report a comparison group. It reports studies of Chinese patent medicines and formulas, plus Liu Zi Jue exercise, moxibustion, and combined rehabilitation. Zhong et al treated 150 participants discharged after COVID-19 with individualized TCM for 3 to 6 months and reported improvement in clinical symptoms, lung function, and a balanced body constitution. The review lists trials of Shumian capsules, Ludangshen oral liquid, Bufei Huoxue capsules, Jinshuibao capsules, Shengmaiyin oral liquid, Shugan Jieyu capsule, Xiangsha Liujun pills, Qingjin Yiqi granules, and formulas, with sample sizes including n = 200 (G1 = 100, G2 = 100), n = 131 (G1 = 66, G2 = 65), n = 388 (G1 = 194, G2 = 194), and n = 96 (G1 = 64, G2 = 32). Pang et al reported better improvement in modified Medical Research Council scale and Borg scale data compared with control, and no treatment-related adverse events were observed among 388 patients. Tao et al reported better TCM symptom score, St. George’s Respiratory Questionnaire score, total treatment efficiency, pulse oxygen saturation level, and 6 minute walking distance data than control. The authors state further high-quality studies are needed.

  67. Research progress on pathogenesis of chronic fatigue syndrome and treatment of traditional Chinese and Western medicine.2024 · review
    Summary

    This comprehensive review synthesized recent literature on Chronic Fatigue Syndrome (CFS) pathogenesis and traditional Chinese and Western medicine treatments; it did not enroll or analyze its own patient cohort, so setting was not reported. Cited studies described varied interventions. Shu et al. randomized 30 CFS patients to acupuncture or moxibustion at Zusanli and Guanyuan; after 4 and 10 weeks both alleviated fatigue symptoms by modulating the vagus nerve, with acupuncture showing superior short-term and moxibustion enhanced long-term clinical efficacy. Luo et al. studied 60 female CFS patients receiving 30-min or 60-min moxibustion three times per week for four weeks; 60-min moxibustion showed advantages for fatigue and depression. Qi Fengjun et al. allocated 60 CFS patients to massage or acupuncture for two treatment courses each lasting 10 days; massage showed significant therapeutic benefits. Liang Weili et al. divided 70 CFS patients; oral medication plus herbal-cake moxibustion was more efficacious than oral medication alone for fatigue and sleep quality. Borody et al. reported FMT therapeutic efficacy in 70% of cases (42 out of 60) with gastrointestinal symptoms. Adamson et al. observed improvement in 995 CFS patients after cognitive-behavioral and psychological interventions. Harms included lower incidence of nausea and diarrhea with moxibustion plus paroxetine than paroxetine alone; in a Norwegian survey approximately 80% of patients reported decline in health status after graded exercise therapy. The authors stated limitations including lack of rigorous trial design and safety data.

  68. Chronic inflammatory response syndrome: a review of the evidence of clinical efficacy of treatment.2024 · review
    Summary

    This literature review searched EBSCOhost Academic Search Premier, Proquest, Google Scholar, and the Cochrane Library in June 2022 for published treatments for chronic inflammatory response syndrome (CIRS), ME/CFS, and sick building syndrome. No patients were enrolled by the review; no comparison group, randomization, or follow-up duration was reported. The review reports 13 articles comprising 14 studies on CIRS treatment and also reviews CFS treatment studies. Named CIRS study sizes included 8, 13, 28, 14, 21, 156/111, 20, 35/4, 100, and 68/23. The review states the only treatment with documented clinical efficacy was the Shoemaker Protocol, described in 11 of the 13 articles; table entries list cholestyramine and vasoactive intestinal peptide as successful, while Rea’s antigen intradermal treatments had lack of objective data. CFS studies listed sizes including 49, 1518, 1030, 2036, 62, 409, 101, 171, 33, 32/18, 23, and 218; findings included some benefit for aripiprazole in 101 patients, high frequency of response for low-dose naltrexone in 218, and CBT/GET reported beneficial in six studies but noncurative. Reported side effects include constipation from cholestyramine, hyponatremia from desmopressin, and light-headedness from vasoactive intestinal peptides; medication intolerance was a barrier.

  69. Research progress in the treatment of chronic fatigue syndrome through interventions targeting the hypothalamus-pituitary-adrenal axis.2024 · review
    Summary

    This review examined treatments targeting the hypothalamic-pituitary-adrenal axis in chronic fatigue syndrome (CFS). It included seven RCTs of traditional Chinese medicine (TCM) methods, with sample sizes of 41, 30, 30, 36, 30, 33, and 20 individuals with CFS. No setting was reported. Treatments included pestle needle therapy plus electric acupuncture, Fuyang cupping, Lixujieyu decoction with or without five-element gongdiao music, scalp acupuncture, acupoint acupuncture with a TCM patch, and electric acupuncture; comparisons included electric acupuncture, massage, chiropracty, and cupping, Chinese medicine alone, music alone, no treatment, Vicodin, adenosine triphosphate, and oryzanol, and no therapeutic operation. Treatment duration was not reported. Outcomes were ACTH, CORT and MT levels and circadian measures. Some studies reported ACTH levels significantly higher after treatment in both groups, CORT significantly lower after treatment in both groups, or CORT significantly higher after treatment in both groups; one reported no significant change in control-group serum CORT. The review also states randomized controlled trials have shown beneficial effects of hydrocortisone for some patients but overall evidence is insufficient; long-term treatment is associated with adverse effects including Cushing’s syndrome, osteoporosis, extreme mood changes and seizures. Withdrawals were not reported. The authors state the TCM RCTs have design, allocation concealment, blinding and safety-reporting deficiencies, limiting interpretation.

  70. Diagnostische Überlegungen und therapeutische Ansätze zu PostCOVID-19 mit Chinesischer Medizin Post COVID-19: diagnostic considerations and therapy options offered by Chinese Medicine2023 · review
    Summary

    This review (Überblick) summarizes treatment options from Chinese Medicine for LongCOVID, PostCOVID and Chronic Fatigue Syndrome/Myalgic Encephalomyelitis (CFS/ME). No patients were enrolled in this paper; it reports findings from other studies. It reviews acupuncture/moxibustion, acupressure, qigong and Chinese herbal medicine. A systematic review with meta-analysis of 31 studies ranked a combination of acupuncture and moxibustion highest for reduction of fatigue symptoms, followed by acupuncture or moxibustion alone, Chinese herbal formulas, Western medicine and sham acupuncture. A review with meta-analysis of 51 RCTs (49 Chinese) also found the strongest effect on general fatigue score for a combination of moxibustion and acupuncture. A systematic review of moxibustion found moxibustion significantly superior to control procedures on various fatigue scales, with Gaohuang moxibustion showing the strongest effect. Two RCTs of qigong in CFS/ME were described: one in 137 patients with CFS using WuXingPingHengGong qigong reported a significant and clinically relevant effect on the Chalder Fatigue Scale and effects on anxiety/depression scales; another in 150 CFS/ME patients using Baduanjin qigong reported a clinically relevant improvement in the Chalder Fatigue Scale (mean 12 points), HADS depression scale and sleep quality only in the qigong group. A systematic review of 84 RCTs of Chinese herbal medicine reported significant improvements in fatigue severity, mood and clinical symptom score, and significant increases in IgA, IgG and IgM antibody titers in CHM arms. No side effects or withdrawals are reported for this review. The authors state that study quality was low overall, that data for PCS are limited, and that evidence for qigong in CFS is thin.

  71. Complementary and Alternative Medicine for Long COVID: Scoping Review and Bibliometric Analysis.2022 · review
    Summary

    This scoping review and bibliometric analysis asked what published evidence exists on complementary and alternative medicine (CAM) for long COVID and long-term management of COVID-19 survivors. The authors searched MEDLINE, Embase, and Cochrane Library from inception until November 2021 and included 16 publications: 2 clinical studies and 14 study protocols of systematic reviews or clinical studies. The two clinical studies examined Chinese herbal medicine (CHM) decoctions in patients after COVID-19 infection; one was a prospective case-control study and the other a single case report. The text does not report treatment duration, a comparison group, or numbers of patients. Outcomes in the included publications were dyspnea or pulmonary dysfunction, quality of life, olfactory dysfunction, and psychological symptoms. The two clinical studies reported CHM decoctions as relieving symptoms of pulmonary dysfunction after COVID-19 infection; no numerical result, no side-effect count, no withdrawal, and no worsening was recorded. The authors state a lack of published studies and limited evidence for CHM decoctions. They state limits: only a small number of publications available; only a limited number of symptoms covered; no search of trial and review registries; and possible publication bias from the limited search. Registration: CRD42021281526.

  72. Theory: Treatments for Prolonged ICU Patients May Provide New Therapeutic Avenues for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS).2021 · review
    Summary

    This paper is an overview of treatment trials for prolonged intensive care unit (ICU) patients, related to ME/CFS; it reports no study enrollment or analysis numbers for an own cohort. It discusses trials of peripheral hormones and pituitary secretagogues. In fibromyalgia, Lowe et al. reported "significant improvement in clinical symptoms were recorded in T3 phases compared to baseline and placebo phases" with T3 at 75–150 mcg/day. Teitelbaum et al. reported that euthyroid ME/CFS and fibromyalgia patients given T4 (Synthroid) or naturally desiccated thyroid hormone (Armor Thyroid) "in addition to adrenal hormones, vitamins, minerals, and antibiotics—also experienced significant improvements." In prolonged critical illness, van den Berghe et al. reported that GHRH or GHRP-2 "reactivated the pulsatile secretion of GH by the pituitary, and the plasma concentrations of IGF-1 and IGFBP-3 increased"; TRH reactivated pulsatile TSH and increased T4 and T3; reverse T3 also increased. The paper states that "somewhat higher doses of hydrocortisone (25–35 mg per day) lead to a moderate decrease in endogenous adrenocorticotropic hormone (ACTH) and cortisol production in ME/CFS patients." Harms include "a large-scale double-blind randomized control study of rhGH infusions undertaken in 1999 resulted in increased mortality of critically ill patients." The authors state limitations: "ME/CFS and prolonged critical illness are not identical illnesses."

  73. Advances in Clinical Research on Traditional Chinese Medicine Treatment of Chronic Fatigue Syndrome.2020 · review
    Summary

    This review summarized clinical research on traditional Chinese medicine for chronic fatigue syndrome (CFS), described as CFS or myositis encephalomyelitis (ME). The authors searched PubMed, Web of Science, JAMA Network, CNKI, SinoMed and WanFang Data (2010~2020.3 and 2015~2020.3) and included 77 articles, 20 in English and 57 in Chinese. The reviewed treatments included herbal decoctions and proprietary Chinese medicines, moxibustion, acupuncture, tuina, cupping, and combinations of these. Many summarized studies reported higher total effective rates in observation groups than in control groups; the review did not pool these into a single comparison. Adverse drug reactions were mentioned for an estradiol patch study, without counts. The authors state that exact efficacy is still controversial. They report that diagnostic criteria, treatment methods and efficacy evaluations lack consensus, that repeated experiments were lacking, and that the level of evidence is not good enough.

  74. Traditional chinese medicine for chronic fatigue syndrome.2010 · review
    Summary

    This review examines traditional Chinese medicine for chronic fatigue syndrome (CFS). It states that CFS has no definitive treatment and that Western drug therapy is often associated with side-effects, so complementary and alternative medicine is common. The paper is not a new cohort or trial; it reviews ancient TCM records and cited clinical studies of herbal prescriptions and crude drugs. Cited studies include a randomized trial of Bu-Zhong-Yi-Qi-Tang with Xiao-Chai-Hu-Tang in 38 CFS patients, in which 18 patients were able to resume normal work and daily activity while symptoms of 16 additional patients were relieved. Ren-Shen-Yang-Rong-Tang was used in 134 CFS patients, and 98 returned to work or school. In a randomized controlled trial of Ginseng in 76 patients, fatigue severity and duration were significantly improved; at 2 months this applied to 45 subjects who had less severe fatigue. Some studies showed no difference between Ginseng and placebo on relieving fatigue; Wiklund’s controlled trial found no difference for sleep dysfunction despite benefits for alertness, relaxation, appetite and quality of life. Reported harms include cerebral impairment and general malaise and fatigue with fluorite, mild poor appetite, dyspepsia and abdominal distension with NADH, and intense side-effects in 82% of subjects treated with IgG. No setting or patient origin is reported for the reviewed studies. The authors state that large randomized controlled trials are required.

A little hope, every Sunday

New recovery stories and data-driven research on ME/CFS and long COVID. Ideas worth considering, and the evidence behind them.

Free · Unsubscribe anytime